Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: firstname.lastname@example.org. Type 508 Accommodation in the subject line of e-mail.
Prevention and Control of Influenza
Recommendations of the Advisory Committee on Immunization
Nicole M. Smith, PhD1
Joseph S. Bresee, MD1
David K. Shay, MD1
Timothy M. Uyeki, MD1
Nancy J. Cox, PhD1
Raymond A. Strikas, MD2 1Influenza Division (proposed)
2Immunization Services Division
National Center for Immunization and Respiratory Diseases (proposed)
The material in this report originated in the National Center for Immunization and Respiratory Diseases (proposed), Anne Schuchat, MD,
Director; Influenza Division (proposed), Nancy Cox, PhD, (Acting) Director; and Immunization Services Division, Lance Rodewald, Director.
Corresponding preparer: Joseph Bresee, MD, Influenza Division, National Center for Immunization and Respiratory Diseases, 1600 Clifton Road,
N.E., MS A-32, Atlanta, GA 30333. Telephone:
404-639-3747; Fax: 404-639-3866; E-mail: email@example.com.
This report updates the 2005 recommendations by the Advisory Committee on Immunization Practices (ACIP)
regarding the use of influenza vaccine and antiviral agents
(CDC. Prevention and control of influenza: recommendations of
the Advisory Committee on Immunization Practices [ACIP]. MMWR 2005;54[No.
RR-8]:1--44). The 2006 recommendations include new and updated information. Principal changes include 1) recommending vaccination of
children aged 24--59 months and their household contacts and out-of-home caregivers against influenza; 2) highlighting
the importance of administering 2 doses of influenza vaccine for children aged 6 months--<9 years who were
previously unvaccinated; 3) advising health-care providers, those planning organized campaigns, and state and local public
health agencies to a) develop plans for expanding outreach and infrastructure to vaccinate more persons than the previous year and
b) develop contingency plans for the timing and prioritization of administering influenza vaccine, if the supply of vaccine
is delayed and/or reduced; 4) reminding providers that they should routinely offer influenza vaccine to patients throughout
the influenza season; 5) recommending that neither amantadine nor rimantadine be used for the treatment or
chemoprophylaxis of influenza A in the United States until evidence of susceptibility to these antiviral medications has been
re-established among circulating influenza A viruses; and 6) using the 2006--07 trivalent influenza vaccine virus strains:
A/New Caledonia/20/1999 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like antigens. For the
A/Wisconsin/67/2005 (H3N2)-like antigen, manufacturers may use the antigenically equivalent A/Hiroshima/52/2005
virus; for the B/Malaysia/2506/2004-like antigen, manufacturers may use the antigenically equivalent B/Ohio/1/2005 virus.
A link to this report and other information can be accessed at
In the United States, epidemics of influenza typically occur during the winter months and have been associated with
an average of approximately 36,000 deaths per year in the United States during 1990--1999
(1). Influenza viruses cause disease among all age groups
(2--4). Rates of infection are highest among children, but rates of serious illness and death are
highest among persons aged >65 years, children aged <2 years, and persons of any age who have medical conditions that place
them at increased risk for complications from influenza
Influenza vaccination is the primary method for preventing influenza and its severe complications. As indicated in
this report from the Advisory Committee on Immunization Practices (ACIP), annual influenza vaccination is now
recommended for the following groups (Box):
persons at high risk for influenza-related complications and severe disease, including
--- children aged 6--59 months,
--- pregnant women,
--- persons aged >50 years,
--- persons of any age with certain chronic medical conditions; and
persons who live with or care for persons at high risk, including
--- household contacts who have frequent contact with persons at high risk and who can transmit influenza
to those persons at high risk and
--- health-care workers.
Vaccination might prevent hospitalization and death among persons at high risk and might also reduce
influenza-related respiratory illnesses and physician visits among all age groups, prevent otitis media among children, and decrease
work absenteeism among adults (8--18). Although influenza vaccination levels increased substantially during the 1990s,
further improvements in vaccination coverage levels are needed, especially among persons aged <65 years with known risk factors
for influenza complications; among blacks and Hispanics aged
>65 years; among children aged 6--23 months; and among
health-care workers. ACIP recommends using strategies to improve vaccination levels, including using reminder/recall systems
and standing orders programs (19--22). Although influenza vaccination remains the cornerstone for the control of
influenza, information on antiviral medications also is presented in this report because these agents are an important adjunct to vaccine.
Primary Changes and Updates in the Recommendations
The 2006 recommendations include six principal changes or updates:
ACIP recommends that healthy children aged 24--59 months and their household contacts and out-of-home
caregivers be vaccinated against influenza (see Target Groups for Vaccination). This change extends the recommendations
for vaccination of children so that all children aged
6--<59 months receive annual vaccination.
ACIP emphasizes that all children aged 6 months--<9 years who have not been previously vaccinated at any time
with either live, attenuated influenza vaccine (LAIV) or trivalent inactivated influenza vaccine (TIV) should receive 2 doses
of vaccine. Those children aged 6 months--<9 years who receive TIV should have a booster dose of TIV administered
>1 month after the initial dose, before the onset of influenza season, if possible. Those children aged 5--<9 years who
receive LAIV should have a second dose of LAIV 6--10 weeks after the initial dose, before the influenza season, if possible. If
a child aged 6 months--<9 years received influenza vaccine for the first time during a previous season but did not receive
a second dose of vaccine within the same season, only 1 dose of vaccine should be administered this season (see
Efficacy and Effectiveness of Inactivated Influenza Vaccine, Children; TIV Dosage; and LAIV Dosage and
To ensure optimal use of available doses of influenza vaccine, projected to be approximately 100 million doses,
health-care providers, those planning organized campaigns, and state and local public health agencies should 1) develop plans
for expanding outreach and infrastructure to vaccinate more persons than
during the previous year and 2) develop
contingency plans for the timing and prioritization of administering influenza vaccine, if the supply of vaccine is delayed and/or
reduced because of the complexity of the production process (see Influenza Vaccine Supply and Timing of Annual
ACIP emphasizes that influenza vaccine should continue to be offered throughout the influenza season even
after influenza activity has been documented in a community. In addition, ACIP encourages all community vaccinators
and public health agencies to schedule clinics that serve target groups and to help extend the routine vaccination season
by offering at least one vaccination clinic in December (see Influenza Vaccine Supply and Timing of Annual
ACIP recommends that neither amantadine nor rimantadine be used for the treatment or chemoprophylaxis of
influenza A in the United States because of recent data indicating widespread resistance of influenza virus to these
medications (23,24). Until susceptibility to adamantanes has been re-established among circulating influenza A viruses, oseltamivir
or zanamivir may be prescribed if antiviral treatment or chemoprophylaxis of influenza is indicated (see
Recommendations for Using Antiviral Agents for Influenza).
The 2006--07 trivalent vaccine virus strains are A/New Caledonia/20/1999 (H1N1)-like,
A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like antigens. For the A/Wisconsin/67/2005 (H3N2)-like
antigen, manufacturers may use the antigenically equivalent
A/Hiroshima/52/2005 virus; for the
B/Malaysia/2506/2004-like antigen, manufacturers may use the antigenically equivalent B/Ohio/1/2005 virus (see Influenza Vaccine Composition).
Influenza and Its Burden
Biology of Influenza
Influenza A and B are the two types of influenza viruses that cause epidemic human disease
(25). Influenza A viruses are further categorized into subtypes on the basis of two surface antigens: hemagglutinin and neuraminidase. Influenza B
viruses are not categorized into subtypes. Since 1977, influenza A (H1N1) viruses, influenza A (H3N2) viruses, and influenza
B viruses have circulated globally. In 2001, influenza A (H1N2) viruses that probably emerged after genetic
reassortment between human A (H1N1) and A (H3N2) viruses began circulating widely. Both influenza A and B viruses are
further separated into groups on the basis of antigenic characteristics. New influenza virus variants result from frequent
antigenic change (i.e., antigenic drift) resulting from point mutations that occur during viral replication. Influenza B viruses
undergo antigenic drift less rapidly than influenza A viruses.
Immunity to the surface antigens, particularly the hemagglutinin, reduces the likelihood of infection and severity of
disease if infection occurs (26). Antibody against one influenza virus type or subtype confers limited or no protection against
another type or subtype of influenza. Furthermore, antibody to one antigenic variant of influenza virus might not completely
protect against a new antigenic variant of the same type or subtype
(27). Frequent development of antigenic variants
through antigenic drift is the virologic basis for seasonal epidemics and the reason for the usual incorporation of one or more
new strains in each year's influenza vaccine. More dramatic antigenic changes, or shifts, occur less frequently and can result in
the emergence of a novel influenza virus with the potential to cause a pandemic.
Clinical Signs and Symptoms of Influenza
Influenza viruses are spread from person to person, primarily through respiratory droplet transmission (e.g., when
an infected person coughs or sneezes in close proximity to an uninfected person)
(25). The typical incubation period for influenza is 1--4 days, with an average of 2 days
(28). Adults can be infectious from the day before symptoms begin
through approximately 5 days after illness onset. Children can be infectious for
>10 days after the onset of symptoms, and
young children also can shed virus before their illness onset. Severely immunocompromised persons can shed virus for weeks
or months (29--32).
Uncomplicated influenza illness is characterized by the abrupt onset of constitutional and respiratory signs and
symptoms (e.g., fever, myalgia, headache, malaise, nonproductive cough, sore throat, and rhinitis)
(33). Among children, otitis media, nausea, and vomiting also are commonly reported with influenza illness
(34--36). Uncomplicated influenza illness
typically resolves after 3--7 days for the majority of persons, although cough and malaise can persist for >2 weeks. However,
among certain persons, influenza can exacerbate underlying medical conditions (e.g., pulmonary or cardiac disease), lead
to secondary bacterial pneumonia or primary influenza viral pneumonia, or occur as part of a coinfection with other viral
or bacterial pathogens (37). Young children with influenza virus infection can have initial symptoms mimicking bacterial
sepsis with high fevers (37,38), and febrile seizures have been reported in up to 20% of children hospitalized with influenza
virus infection (35,39). Influenza virus infection also has been uncommonly associated with encephalopathy, transverse
myelitis, myositis, myocarditis, pericarditis, and Reye syndrome
Respiratory illnesses caused by influenza viruses are difficult to distinguish from illnesses caused by other
respiratory pathogens on the basis of signs and symptoms alone (see Role of Laboratory Diagnosis). Reported sensitivities
and specificities of clinical definitions of influenza infection that include fever and cough in studies primarily among adults
have ranged from 63% to 78% and 55% to 71%, respectively, compared with viral culture
(42,43). Sensitivity and predictive value of clinical definitions can vary, depending on the degree of co-circulation of other respiratory pathogens and the level
of influenza activity(44). A study of older nonhospitalized patients determined that the presence of fever, cough, and
acute onset had a positive predictive value of only 30% for influenza
(45), whereas a study of hospitalized older patients
with chronic cardiopulmonary disease determined that a combination of fever, cough, and illness of <7 days was 78% sensitive
and 73% specific for influenza (46). A study of vaccinated older persons with chronic lung disease indicated that cough was
not predictive of influenza virus infection, although having a fever or feverishness was 68% sensitive and 54% specific
for influenza virus infection (47). These results highlight the challenges of identifying influenza illness in the absence
of laboratory confirmation.
Hospitalizations and Deaths from Influenza
The risks for complications, hospitalizations, and deaths from influenza are higher among persons aged
>65 years, young children, and persons of any age with certain underlying health conditions (see Persons at Increased Risk for
Complications) than among healthy older children and younger adults
(1,6,8,48--56). Estimated rates of influenza-associated
hospitalizations have varied substantially by age group in studies conducted during different influenza epidemics (Table 1).
Among children aged <5 years, hospitalization rates have ranged from approximately 500/100,000 children for those
with high-risk medical conditions to 100/100,000 children for those without high-risk medical conditions
(57--60). Hospitalization rates among children aged <24 months are comparable to rates reported among persons aged
>65 years (59,60) (Table 1).
During seasonal influenza epidemics from 1979--80 through 2000--01, the estimated overall number of
influenza-associated hospitalizations in the United States ranged from approximately 54,000 to 430,000/epidemic. An average
of approximately 226,000 influenza-related excess hospitalizations occurred per year, and 63% of all hospitalizations
occurred among persons aged >65 years
(61). Since the 1968 influenza A (H3N2) virus pandemic, the number of
influenza-associated hospitalizations is generally greater during seasonal influenza epidemics caused by type A (H3N2) viruses than seasons
in which other influenza virus types predominate
Influenza-related deaths can result from pneumonia and from exacerbations of cardiopulmonary conditions and
other chronic diseases. Deaths of adults aged
>65 years account for >90% of deaths attributed to pneumonia and influenza
(1,54). In one study, approximately 19,000 influenza-associated pulmonary and circulatory deaths per influenza season
occurred during 1976--1990, compared with approximately 36,000 deaths during 1990--1999
(1). Estimated rates of influenza-associated pulmonary and circulatory deaths/100,000 persons were 0.4--0.6 among persons aged 0--49 years, 7.5
among persons aged 50--64 years, and 98.3 among persons aged
>65 years. In the United States, the number of
influenza-associated deaths has increased in part because the number of older persons is increasing, particularly persons aged
>85 years (63). In addition, influenza seasons in which influenza A (H3N2) viruses predominate are associated with higher
mortality (64); influenza A (H3N2) viruses predominated in 90% of influenza seasons during 1990--1999, compared with 57%
of influenza seasons during 1976--1990 (1).
Deaths from influenza are uncommon among children both with and without high-risk conditions, but do occur
(65,66). A study that modeled influenza-related deaths estimated that an average of 92 deaths (0.4 deaths per 100,000)
occurred among children aged <5 years annually during the 1990s, compared with 32,651 deaths (98.3 per 100,000) among
adults aged >65 years (1). Of 153 laboratory-confirmed
influenza-related pediatric deaths reported from 40 states during the
2003--04 influenza season, 96 (63%) were among children aged <5 years. Sixty-four (70%) of the 92 children aged 2--17 years
with influenza who died had no underlying medical condition previously associated with an increased risk for
influenza-related complications (67).
Options for Controlling Influenza
In the United States, the primary option for reducing the effect of influenza is through annual vaccination. Inactivated
(i.e., killed virus) influenza vaccines and LAIV are licensed and available for use in the United States (see Recommendations
for Using Inactivated and Live, Attenuated Influenza Vaccines). Vaccination coverage can be increased by administering
vaccine to persons during hospitalizations or routine health-care visits, as well as at pharmacies, grocery stores, workplaces, or
other locations in the community before the influenza season, therefore making special visits to physicians' offices or
clinics unnecessary. Achieving increased vaccination rates among persons living in closed settings (e.g., nursing homes and
other chronic-care facilities) and among staff can reduce the risk for outbreaks
(13), especially when vaccine and circulating
strains are well-matched. Vaccination of health-care workers and other persons in close contact with persons at increased risk
for severe influenza illness also can reduce transmission of influenza and subsequent influenza-related complications.
Antiviral drugs used for chemoprophylaxis or treatment of influenza are adjuncts to vaccine (see Recommendations for Using
Antiviral Agents for Influenza) but are not substitutes for annual
Influenza Vaccine Composition
Both the inactivated and live, attenuated vaccines prepared for the 2006--07 season will include A/New
Caledonia/20/1999 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like antigens (for the
A/Wisconsin/67/2005 [H3N2]-like antigen, manufacturers may use the antigenically equivalent A/Hiroshima/52/2005 virus, and for the
Malaysia/2506/2004-like antigen, manufacturers may use the antigenically equivalent B/Ohio/1/2005 virus). These
viruses will be used because they are representative of influenza viruses that are anticipated to circulate in the United States
during the 2006--07 influenza season and have favorable growth properties in eggs. Because circulating influenza A (H1N2)
viruses are reassortants of influenza A (H1N1) and A (H3N2) viruses, antibodies directed against influenza A (H1N1) and
influenza (H3N2) vaccine strains should provide protection against the circulating influenza A (H1N2) viruses. Influenza viruses
for both TIV and LAIV are initially grown in embryonated hens eggs, and, therefore, might contain limited amounts of
residual egg protein. Therefore, persons with a history of severe hypersensitivity, such as anaphylaxis, to eggs should not
receive influenza vaccine.
For the inactivated vaccines, the vaccine viruses are made noninfectious (i.e., inactivated or killed)
(68). Only subvirion and purified surface antigen preparations of the inactivated vaccine are available. Manufacturing processes vary by
manufacturer. Manufacturers might use different compounds to inactivate influenza viruses and add antibiotics to prevent
bacterial contamination. Package inserts should be consulted for additional information.
Comparison of LAIV with Inactivated Influenza Vaccine
Both inactivated influenza vaccine and LAIV are available. Although both types of vaccines are effective, the vaccines
differ in several aspects (Table 2).
Both LAIV and inactivated influenza vaccines contain strains of influenza viruses that are antigenically equivalent to
the annually recommended strains: one influenza A (H3N2) virus, one A (H1N1) virus, and one B virus. Each year, one or
more virus strains might be changed on the basis of global surveillance for influenza viruses and the emergence and spread of
new strains. Viruses for both vaccines are grown in eggs. Both vaccines are administered annually to provide optimal
protection against influenza virus infection (Table 2).
Inactivated influenza vaccine contains killed viruses, and thus cannot produce signs or symptoms of influenza
virus infection. In contrast, LAIV contains live, attenuated viruses and, therefore, has a potential to produce mild signs
or symptoms related to influenza virus infection. LAIV is administered intranasally by sprayer, whereas inactivated
influenza vaccine is administered intramuscularly by injection. LAIV is more expensive than inactivated influenza vaccine, although
the price differential between inactivated vaccine and LAIV has decreased for the 2006--07 season. LAIV is approved only for
use among healthy persons aged 5--49 years; inactivated influenza vaccine is approved for use among persons aged
>6 months, including those who are healthy and those with chronic medical conditions (Table 2).
Efficacy and Effectiveness of Inactivated Influenza Vaccine
The effectiveness of inactivated influenza vaccine depends primarily on the age and immunocompetence of the
vaccine recipient, the degree of similarity between the viruses in the vaccine and those in circulation, and the outcome
being measured. Vaccine efficacy and effectiveness studies might have various endpoints, including the prevention of
medically attended acute respiratory illness (MAARI), prevention of
culture-positive influenza virus illness, prevention of influenza
or pneumonia-associated hospitalizations or deaths, seroconversion to vaccine serotypes, or prevention of seroconversion
to circulating influenza virus subtypes. High postvaccination hemagglutination inhibition antibody titers develop in
the majority of vaccinated children and young adults
(69--71). These antibodies are protective against illness caused by
strains that are antigenically similar to those strains of the same type or subtype included in the vaccine
Children. Children aged >6 months usually acquire protective levels of anti-influenza antibody against specific
influenza virus strains after influenza vaccination
(69,70,74--79), although the antibody response among children at high risk
for influenza-related complications might be lower than among healthy children
(80,81). A 2-year randomized study of
children aged 6--24 months determined that 89% of children seroconverted to all three vaccine strains during both years
(82). During year 1, among 411 children, vaccine efficacy was 66% (95% confidence interval [CI] = 34%--82%) against
culture-confirmed influenza (attack rates: 5.5% and 15.9% among vaccine and placebo groups, respectively). During year 2, among
375 children, vaccine efficacy was -7% (CI = -247%--67%; attack rates: 3.6% and 3.3% among vaccine and placebo
respectively); the second year exhibited lower attack rates overall and was considered a mild season. In both years of this
study, the vaccine strains were well- matched to the circulating influenza virus strains.
A randomized study among children aged 1--15 years also demonstrated that inactivated influenza vaccine was 77%
and 91% effective against influenza respiratory illness during H3N2 and H1N1 years, respectively
(71). One study documented a vaccine efficacy of 56% against influenza illness among healthy children aged 3--9 years
(83), and another study determined vaccine efficacy against influenza type B infection and influenza type A infection of 22%--54% and 60%--78%
among children with asthma aged 2--6 years and 7--14 years, respectively
(84). Two studies have documented that TIV
vaccine decreases the incidence of influenza-associated otitis media among young children by approximately 30%
(16,17), whereas a third study determined that vaccination did not reduce the burden of acute otitis media
Effectiveness of One Dose versus Two Doses of Influenza Vaccine Among Previously Unvaccinated Children Aged
<9 Years. Vaccine effectiveness is lower among previously unvaccinated children aged <9 years if they have only received 1
dose of influenza vaccine, compared with children who have received 2 doses. A retrospective study among approximately
5,000 children aged 6--23 months conducted during a year with a suboptimal vaccine match indicated vaccine effectiveness of
49% against medically attended, clinically diagnosed pneumonia or influenza among children who had received 2 doses
of influenza vaccine. No effectiveness was demonstrated among children who had received only 1 dose of influenza
vaccine, illustrating the importance of administering 2 doses of vaccine to previously unvaccinated children aged <9 years
(85). Similar results were observed in a case-control study of children aged 6--59 months with
A study assessing protective antibody responses after 1 and 2 doses of vaccine among vaccine-naive children aged 5--8 years
also demonstrated the importance of compliance with the 2-dose recommendation
(87). When the vaccine antigens do
not change from one season to the next, priming with a single dose of vaccine in the spring, followed by a dose in the fall might result
in similar antibody responses to a 2-dose regimen in the fall
Adults Aged <65 Years. When the vaccine and circulating viruses are antigenically similar, influenza vaccine
typically prevents influenza illness among approximately 70%--90% of healthy adults aged <65 years
(9,12,90,91). Vaccination of healthy adults also has resulted in decreased work absenteeism and decreased use of health-care resources, including use
of antibiotics, when the vaccine and circulating viruses are well-matched
(9--12,91,92). In a case-control study of adults
aged 50--64 years with laboratory-confirmed influenza during the 2003--04 season when the vaccine and circulating viruses
were not well-matched, vaccine effectiveness was estimated to be 52% among healthy persons and 38% among those with one
or more high-risk conditions (93).
Adults Aged >65 Years. An important benefit of the influenza vaccine is its ability to help prevent secondary
complications and reduce the risk for influenza-related hospitalization and death among adults aged
>65 years with and without high-risk medical conditions (e.g., heart disease and diabetes)
(13--15,18,94,95). Older persons and persons with certain
chronic diseases might have lower postvaccination antibody titers than healthy young adults and can remain susceptible to
influenza virus infection and influenza-related upper respiratory tract illness
(96--98). A randomized trial among
noninstitutionalized persons aged >60 years reported a vaccine efficacy of 58% against influenza respiratory illness but indicated that
efficacy might be lower among those aged
>70 years (99). However, among older persons not living in nursing homes or
similar chronic-care facilities, influenza vaccine is 30%--70% effective in preventing hospitalization for pneumonia and
influenza (15,100). Among older persons who reside in nursing homes, influenza vaccine is most effective in preventing severe
illness, secondary complications, and deaths. In this population, the vaccine can be 50%--60% effective in preventing
influenza-related hospitalization or pneumonia and 80% effective in preventing
influenza-related death, although the effectiveness
in preventing influenza illness often ranges from 30% to 40%
Efficacy and Effectiveness of LAIV
The immunogenicity of the approved LAIV has been assessed in multiple studies
(104--110), which included approximately 100 children aged 5--17 years and approximately 300 adults aged 18--49 years. LAIV virus strains
replicate primarily in nasopharyngeal epithelial cells. The protective mechanisms induced by vaccination with LAIV are not
completely understood but appear to involve both serum and nasal secretory antibodies. No single laboratory measurement
closely correlates with protective immunity induced by LAIV.
Healthy Children. A randomized, double-blind, placebo-controlled trial among 1,602 healthy children initially aged
15--71 months assessed the efficacy of trivalent LAIV against culture-confirmed influenza during two seasons
(111,112). This trial included subsets of 238 healthy children (163 vaccinees and 75 placebo recipients) aged 60--71 months who received
doses and 74 children (54 vaccinees and 20 placebo recipients) aged 60--71 months who received a single dose during
season one, and a subset of 544 children (375 vaccinees and 169 placebo recipients) aged 60--84 months during season
two. Children who continued in the study remained in the same study group. In season one, when vaccine and circulating
virus strains were well-matched, efficacy was 93% for participants who received 2 doses of LAIV. In season two, when the
A (H3N2) component was not well-matched between vaccine and circulating virus strains, efficacy was 86% overall.
The vaccine was 92% efficacious in preventing
culture-confirmed influenza during the two-season study. Other results included
a 27% reduction in febrile otitis media and a 28% reduction in otitis media with concomitant antibiotic use. Receipt of
LAIV also resulted in 21% fewer febrile illnesses. A review of LAIV effectiveness in children aged 18 months--18 years
found effectiveness against MAARI of 18% but greater estimated efficacy levels: 92% against influenza A (H1N1) and 66%
against an influenza B drift variant (113).
Healthy Adults. A randomized, double-blind,
placebo-controlled trial among 4,561 healthy working adults aged
18--64 years assessed multiple endpoints, including reductions in self-reported respiratory tract illness without
laboratory confirmation, absenteeism, health-care visits, and medication use during peak and total influenza outbreak periods
(114). The study was conducted during the 1997--98 influenza season, when the vaccine and circulating A (H3N2) strains were not
well-matched. During peak outbreak periods, no difference in febrile illnesses between LAIV and placebo recipients was
observed. However, vaccination was associated with reductions in severe febrile illnesses of 19% and febrile upper respiratory
tract illnesses of 24%. Vaccination also was associated with fewer days of illness, fewer days of work lost, fewer days with
health-care--provider visits, and reduced use of prescription antibiotics and over-the-counter medications. Among a subset of
3,637 healthy adults aged 18--49 years, LAIV recipients (n = 2,411) had 26% fewer febrile upper-respiratory illness episodes;
27% fewer lost work days as a result of febrile upper respiratory illness; and 18%--37% fewer days of health-care--provider
visits caused by febrile illness, compared with placebo recipients (n = 1,226). Days of antibiotic use were reduced by 41%--45%
in this age subset.
A randomized, double-blind, placebo-controlled challenge study among 92 healthy adults (LAIV, n = 29; placebo, n =
31; inactivated influenza vaccine, n = 32) aged 18--41 years assessed the efficacy of both LAIV and inactivated vaccine
(115). The overall efficacy of LAIV and inactivated influenza vaccine in preventing laboratory-documented influenza from all
three influenza strains combined was 85% and 71%, respectively, on the basis of experimental challenge by viruses to which
study participants were susceptible before vaccination. The difference in efficacy between the two vaccines was not
Cost-Effectiveness of Influenza Vaccine
Influenza vaccination can reduce both health-care costs and productivity losses associated with influenza illness. Studies
of influenza vaccination of persons aged
>65 years conducted in the United States have reported substantial reductions
in hospitalizations and deaths and overall societal costs savings
(15,100,104). Studies of adults aged <65 years have
indicated that vaccination can reduce both direct medical costs and indirect costs from work absenteeism
(8,10--12,91,116). Reductions of 13%--44% in health-care--provider visits, 18%--45% in lost workdays, 18%--28% in days working
with reduced effectiveness, and 25% in antibiotic use for
influenza-associated illnesses have been reported
(10,12,117,118). One cost-effectiveness analysis estimated a cost of approximately $60--$4,000/illness averted among healthy persons aged
18--64 years, depending on the cost of vaccination, the influenza attack rate, and vaccine effectiveness against
influenza-like illness (ILI) (91). Another cost-benefit economic study estimated an average annual savings of $13.66/person vaccinated
(119). In the second study, 78% of all costs prevented were costs from lost work productivity, whereas the first study did not
include productivity losses from influenza illness.
Economic studies specifically evaluating the
cost-effectiveness of vaccinating persons aged 50--64 years are not
available, and the number of studies that examine the economics of routinely vaccinating children with TIV or LAIV are
limited (8,120--123). However, in a study of inactivated vaccine that included all age groups, cost utility (i.e., cost per year of
healthy life gained) improved with increasing age and among those with chronic medical conditions
(8). Among persons aged >65 years, vaccination resulted in a net savings per quality-adjusted life year (QALY) gained, whereas among younger age
groups, vaccination resulted in costs of $23--$256/QALY.
In addition to estimating the economic cost associated with influenza disease, studies have assessed the public's
perception of preventing influenza morbidity. Less than half of respondents to a survey on public perception of the value of
influenza morbidity reported that they would trade any time from their own life to prevent a case of uncomplicated
influenza in a hypothetical child (124). When asked about their willingness to pay to prevent a hypothetical child from having
an uncomplicated case of influenza, the median willingness-to-pay amount was $100 for a child aged 14 years and $175 for
a child aged 1 year (124).
Vaccination Coverage Levels
One of the national health objectives for 2010 is to achieve an influenza vaccination coverage level of 90% for persons
aged >65 years (objective no. 14-29a)
(125). Among persons aged >65 years, influenza vaccination levels increased from 33%
in 1989 (126) to 66% in 1999 (127), surpassing the
Healthy People 2000 objective of 60%
(128). Vaccination coverage in this group reached the highest levels recorded (68%) during the 1999--00 influenza season. This estimate was made using
the percentage of adults reporting influenza vaccination during the previous 12 months in the National Health Interview
Survey (NHIS). The NHIS administered during the first and second quarters of each calendar year was used as a proxy measure
of influenza vaccination coverage for the previous influenza season
(127). Possible reasons for increases in influenza
vaccination levels among persons aged >65 years include 1) greater acceptance of preventive medical services by practitioners; 2)
increased delivery and administration of vaccine by health-care providers and sources other than physicians; 3) new
information regarding influenza vaccine effectiveness, cost-effectiveness, and safety; and 4) initiation of Medicare reimbursement
for influenza vaccination in 1993
(8,14,15,101,102,129,130). Since 1997, influenza vaccination levels have increased
more slowly, with an average annual percentage increase of 4% from 1988--89 to 1996--97 versus 1% from 1996--97 to
1998--99. In 2000, a substantial delay in influenza vaccine availability and distribution, followed by a less severe delay in 2001
likely contributed to the lack of progress. However, the slowing of the increase in vaccination levels began before 2000 and is
not fully understood.
Estimated national influenza vaccine coverage in 2004 among persons aged
>65 years and 50--64 years was 65% and
36%, respectively, based on 2004 NHIS data (Table 3). The estimated vaccination coverage among adults with high-risk
conditions aged 18--49 years and 50--64 years was 26% and 46%, respectively, substantially lower than the
Healthy People 2000 and 2010 objective of 60%
(125,128). Continued annual monitoring is needed to determine the effects of vaccine supply
delays and shortages, changes in influenza vaccination recommendations and target groups for vaccination, reimbursement rates
for vaccine and vaccine administration, and other factors related to vaccination coverage among adults and children.
New strategies to improve coverage will be needed to achieve the
Healthy People 2010 objective (21,22).
Reducing racial and ethnic health disparities, including disparities in vaccination coverage, is an overarching national
goal (125). Although estimated influenza vaccination coverage for the 1999--00 season reached the highest levels recorded
among older black, Hispanic, and white populations, vaccination levels among blacks and Hispanics continue to lag behind
those among whites (127,131). Estimated vaccination coverage levels based on 2004 NHIS data among persons aged
>65 years were 67% among non-Hispanic whites, 45% among non-Hispanic blacks, and 55% among Hispanics (CDC,
unpublished data, 2006). Among Medicare beneficiaries, unequal access to care might not be the only factor in contributing
toward disparity levels in influenza vaccination; other key factors include having patients that actively seek vaccination and
providers that recommend vaccination
In 1997 and 1998, vaccination coverage estimates among nursing home residents were 64%--82% and 83%,
respectively (134,135). The Healthy People
2010 goal is to achieve influenza vaccination of 90% among nursing home residents,
an increase from the Healthy People 2000 goal of 80%
Reported vaccination levels are low among children at increased risk for influenza complications. One study
conducted among patients in health maintenance organizations (HMOs) documented influenza vaccination percentages ranging
from 9% to 10% among children with asthma
(136). A 25% vaccination level was reported among children with severe
to moderate asthma who attended an allergy and immunology clinic
(137). However, a study conducted in a pediatric
clinic demonstrated an increase in the vaccination percentage of children with asthma or reactive airways disease from 5% to
32% after implementing a reminder/recall system
(138). One study documented 79% vaccination coverage among
children attending a cystic fibrosis treatment center
(139). According to 2004 National Immunization Survey data, during the
second year of the encouragement for vaccination of children aged 6--23 months, 18% received one or more influenza
vaccinations and 8.4% received 2 doses if they were previously unvaccinated
(140). A rapid analysis of influenza vaccination
coverage levels among members of an HMO in Northern California determined that in 2004--05, the first year of
recommendation for vaccination of children aged 6--23 months, their coverage level reached 57%
(141). Data from the Behavioral Risk Factor Surveillance System (BRFSS) collected in February 2005 indicated a national estimate of
48% vaccination coverage for 1 or more doses among children aged 6--23 months and 35% coverage among children aged
2--17 years who had one or more high-risk medical conditions during the 2004--05 season
(142). Increasing vaccination coverage among persons who have high-risk conditions and are aged <65 years, including children at high risk, is the highest
priority for expanding influenza vaccine use. As has been observed for older adults, a physician recommendation for vaccination
and the perception that getting a child vaccinated "is a smart idea" were positively associated with likelihood of vaccination
of children aged 6--23 months (143).
Annual vaccination is recommended for health-care workers. Nonetheless, NHIS 2004 survey data indicated a
vaccination coverage level of only 42% among health-care workers (CDC, unpublished data, 2006). Vaccination of health-care
workers has been associated with reduced work absenteeism
(9) and fewer deaths among nursing home patients
(144,145) and is a high priority for reducing the effect of influenza in health-care settings and for expanding influenza vaccine use
Limited information is available regarding use of influenza vaccine among pregnant women. Among women aged
18--44 years without diabetes responding to the 2001 BRFSS, those who were pregnant were less likely to report
influenza vaccination during the previous 12 months (13.7%) than those women who were not pregnant (16.8%); these
differences were statistically significant
(148). Only 13% of pregnant women reported vaccination according to 2004 NHIS
data, excluding pregnant women who reported diabetes, heart disease, lung disease, and other selected high-risk conditions
(CDC, unpublished data, 2006) (Table 3). These data indicate low compliance with the ACIP recommendations for
pregnant women. In a study of influenza vaccine acceptance by pregnant women, 71% who were offered the vaccine chose to
be vaccinated (149). However, a 1999 survey of obstetricians and gynecologists determined that only 39%
administered influenza vaccine to obstetric patients, although 86% agreed that pregnant women's risk for influenza-related morbidity
and mortality increases during the last two trimesters
Data indicate that self-report of influenza vaccination among adults, compared with extraction from the medical record,
is both a sensitive and specific source of information
(151). Patient self-reports should be accepted as evidence of
influenza vaccination in clinical practice
(151). However, information on the validity of parents' reports of pediatric
influenza vaccination is not yet available.
Recommendations for Using Inactivated and Live, Attenuated
The inactivated influenza vaccine and LAIV can be used to reduce the risk for influenza virus infection and
its complications. TIV is Food and Drug Administration (FDA)-approved for persons aged
>6 months, including those with high-risk conditions, whereas LAIV is approved only for use among healthy persons aged 5--49 years (see
Inactivated Influenza Vaccine Recommendations; and Live, Attenuated Influenza Vaccine Recommendations).
Target Groups for Vaccination
Annual influenza vaccination is recommended for the
Persons at Increased Risk for Complications
Vaccination with inactivated influenza
vaccine is recommended for the following persons who are at increased risk
for severe complications from influenza:
children aged 6--23 months;
children and adolescents (aged 6 months--18 years) who are receiving long-term aspirin therapy and, therefore, might
be at risk for experiencing Reye syndrome after influenza virus infection;
women who will be pregnant during the influenza
adults and children who have chronic disorders of the pulmonary or cardiovascular systems, including
asthma (hypertension is not considered a high-risk condition);
adults and children who have required regular medical follow-up or hospitalization during the preceding year because
of chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or
immunodeficiency (including immunodeficiency caused by medications or by human immunodeficiency virus [HIV]);
adults and children who have any condition (e.g., cognitive dysfunction, spinal cord injuries, seizure disorders, or
other neuromuscular disorders) that can compromise respiratory function or the handling of respiratory secretions or that
can increase the risk for aspiration;
residents of nursing homes and other chronic-care facilities that house persons of any age who have chronic
medical conditions; and
persons aged >65 years.
Vaccination with inactivated influenza
vaccine also is recommended for the following persons because of an increased
risk for influenza-associated clinic, emergency department, or hospital visits, particularly if they have a high-risk
children aged 24--59 months and
persons aged 50--64 years.
Persons Who Live With or Care for Persons at High Risk for Influenza-Related Complications
In addition, to prevent transmission to persons identified above, vaccination with TIV or LAIV is recommended for
the following persons, unless contraindicated:
healthy household contacts and caregivers of children aged 0--59 months and persons at high risk for
severe complications from influenza and
In 2006, approximately 218.1 million persons in the United States will be included in one or more of these target
groups, including 6.0 million children aged 6--23 months, 10.6 million healthy children aged 24--59 months, 44.0 million
persons aged 2--64 years with one or more conditions associated with an increased risk for influenza-related complications,
4.0 million pregnant women, 33.0 million healthy persons aged 50--64 years, approximately 2 million nursing
home residents, 37.2 million persons aged
>65 years, 94.8 million healthy household contacts, and 7.0 million health-care
workers aged <65 years (CDC, unpublished data, 2006).
Additional Information Regarding Vaccination of Specific Populations
Healthy Young Children Aged 6--59 Months
Because children aged 6--23 months are at substantially increased risk for influenza-related hospitalizations and
because children aged 24--59 months are at increased risk for influenza-related clinic and emergency department visits
(152), ACIP recommends vaccination of children aged 6--59 months. The current LAIV and inactivated influenza vaccines are
not approved by FDA for use among children aged <6 months, the pediatric group at greatest risk for
influenza-related complications (58,153,154). Vaccination of their household contacts and out-of-home caregivers also is
recommended because it might decrease the probability of influenza virus infection among these children.
Studies indicate that rates of hospitalization are higher among young children than older children when influenza viruses are
in circulation (57,59--61,62,155--157). The increased rates of hospitalization are comparable with rates for other groups
considered at high risk for influenza-related complications. However, the interpretation of these findings has been confounded
by cocirculation of respiratory syncytial virus that causes serious respiratory viral illness among children and that
frequently circulates during the same time as influenza viruses
(158--160). One study assessed rates of
influenza-associated hospitalizations among the entire U.S. population during 1979--2001 and calculated an average rate of approximately 108 hospitalizations
per 100,000 person-years in children aged <5 years
(48). Two studies have attempted to separate the impact of respiratory
syncytial viruses and influenza viruses on rates of hospitalization among children who do not have high-risk conditions
(58,59). Both studies indicated that otherwise healthy children aged <2 years and possibly children aged 2--4 years are at increased risk
for influenza-related hospitalization compared with older healthy children (Table 1). Among the Tennessee Medicaid
population during 1973--1993, healthy children aged 6 months--2 years had rates of influenza-associated hospitalization comparable with
higher than rates among children aged 3--14 years with high-risk conditions
(58,60). Another Tennessee study indicated
a hospitalization rate per year of 3--4/1,000 healthy children aged <2 years for laboratory-confirmed
The ability of providers to implement the recommendation to vaccinate all children aged 24--59 months during the
2006--07 season, the first year the recommendation will be in place, might vary depending upon vaccine supply (See
Influenza Vaccine Supply and Timing of Annual Influenza Vaccination; and
Influenza-associated excess deaths among pregnant women were documented during the pandemics of 1918--19 and
1957--58 (51,161--163). Case reports and limited studies also indicate that pregnancy can increase the risk for serious
medical complications of influenza
(164--169). One study of influenza vaccination of approximately 2,000 pregnant
women demonstrated no adverse fetal effects associated with inactivated influenza vaccine
(170); similar results were observed in a study of 252 pregnant women who received inactivated influenza vaccine within 6 months of delivery
(171). No such data exist on the safety of LAIV when administered during pregnancy.
TIV is safe for mothers who are breastfeeding and their infants. Because excretion of LAIV in human milk is unknown
and because of the possibility of shedding vaccine virus given the close proximity of a nursing mother and her infant,
caution should be exercised if LAIV is administered to nursing mothers. Breastfeeding does not adversely affect the immune
response and is not a contraindication for vaccination.
Persons Aged 50--64 Years
Vaccination is recommended for persons aged 50--64 years because this group has an increased prevalence of persons
with high-risk conditions. In 2002, approximately 43.6 million persons in the United States were aged 50--64 years, of whom
13.5 million (34%) had one or more high-risk medical conditions
(172). Influenza vaccine has been recommended for this
entire age group to increase the low vaccination levels among persons in this age group with high-risk conditions (see Persons
at Increased Risk for Complications). Age-based strategies are more successful in increasing vaccine coverage than
patient-selection strategies based on medical conditions. Persons aged 50--64 years without high-risk conditions also receive
benefit from vaccination in the form of decreased rates of influenza illness, decreased work absenteeism, and decreased need
for medical visits and medication, including antibiotics
(9--12). Furthermore, 50 years is an age when other preventive
services begin and when routine assessment of vaccination and other preventive services has been recommended
Health-Care Workers and Other Persons Who Can Transmit Influenza to Those at High
Persons who are clinically or asymptomatically infected can transmit influenza virus to persons at high risk
for complications from influenza. Decreasing transmission of influenza from caregivers and household contacts to persons
at high risk might reduce influenza-related deaths among persons at high risk. In two studies, vaccination of health-care
workers was associated with decreased deaths among nursing home patients
(144,145), and hospital-based influenza
outbreaks frequently occur where unvaccinated health-care workers are employed. Administration of LAIV has been demonstrated
to reduce MAARI in contacts of vaccine recipients
(175,176) and to reduce ILI-related economic and medical
consequences (such as work days lost and number of health-care provider visits). In addition to health-care workers, additional groups
that can transmit influenza to persons at high risk and that should be vaccinated include the
employees of assisted living and other residences for persons in groups at high risk,
persons who provide home care to persons in groups at high risk, and
household contacts (including children) of persons in groups at high risk.
In addition, because children aged 0--23 months are at increased risk for influenza-related hospitalization
(58--60), vaccination is recommended for their household contacts and out-of-home caregivers, particularly for contacts of
children aged 0--5 months, because influenza vaccines have not been approved by FDA for use among children aged <6 months
(see Healthy Young Children Aged 6--59 Months).
Healthy persons aged 5--49 years in these groups who are not contacts of severely immunocompromised persons (see
Live, Attenuated Influenza Vaccine Recommendations) can receive either LAIV or inactivated influenza vaccine. All other
persons in this group should receive inactivated influenza
All health-care workers should be vaccinated against influenza annually
(147,177,178). Facilities that employ
health-care workers are strongly encouraged to provide vaccine to workers by using approaches that maximize vaccination levels.
An improvement in vaccination coverage levels might help to protect health-care workers, their patients, and
communities; improve prevention of influenza-associated disease and patient safety; and reduce disease burden. Influenza vaccination
levels among health-care workers should be regularly measured and reported. Although vaccination levels for health-care
workers are typically <40%, with moderate effort, organized campaigns can attain higher levels of vaccination among this
population (146,179). In 2005, seven states had legislation requiring annual influenza vaccination of health-care workers or the
signing of an informed declination (147), and 15 states had regulations regarding vaccination of health-care workers in
long-term--care facilities (180). Physicians, nurses, and other workers in both hospital and outpatient-care settings, including
medical emergency-response workers (e.g., paramedics and emergency medical technicians), should be vaccinated, as
should employees of nursing home and chronic-care facilities who have contact with patients or residents.
Persons Infected with HIV
Limited information is available regarding the frequency and severity of influenza illness or the benefits of
influenza vaccination among persons with HIV infection
(181,182). However, a retrospective study of young and middle-aged
women enrolled in Tennessee's Medicaid program determined that the risk for cardiopulmonary hospitalizations among women
with HIV infection was higher during influenza seasons than during the peri-influenza periods. The risk for hospitalization
was higher for HIV-infected women than for women with other well-recognized high-risk conditions, including chronic heart
and lung diseases (183). Another study estimated that the risk for influenza-related death was 9.4--14.6/10,000 persons
with acquired immunodeficiency syndrome (AIDS), compared with 0.09--0.10/10,000 among all persons aged 25--54 years
and 6.4--7.0/10,000 among persons aged >65 years
(184). Other reports indicate that influenza symptoms might be
prolonged and the risk for complications from influenza increased for certain
HIV-infected persons (185--187).
Vaccination has been demonstrated to produce substantial antibody titers against influenza among vaccinated
HIV-infected persons who have minimal AIDS-related symptoms and high CD4+ T-lymphocyte cell counts
(188--191). A limited, randomized, placebo-controlled trial determined that inactivated influenza vaccine was highly effective in
preventing symptomatic, laboratory-confirmed influenza virus infection among HIV-infected persons with a mean of 400 CD4+
T-lymphocyte cells/mm3; a limited number of persons with CD4+ T-lymphocyte cell counts of <200 were included in
that study (192). A nonrandomized study among
HIV-infected persons determined that influenza vaccination was most
effective among persons with >100 CD4+ cells and among those with <30,000 viral copies of HIV type-1/mL
(187). Among persons who have advanced HIV disease and low CD4+ T-lymphocyte cell counts, inactivated influenza vaccine might not
induce protective antibody titers (190,191); a second dose of vaccine does not improve the immune response in these
One case study determined that HIV RNA (ribonucleic acid) levels increased transiently in one HIV-infected person
after influenza virus infection (193). Studies have demonstrated a transient (i.e., 2--4 week) increase in replication of HIV-1 in
the plasma or peripheral blood mononuclear cells of HIV-infected persons after vaccine administration
(190,194). Other studies using similar laboratory techniques have not documented a substantial increase in the replication of HIV
(195--198). Deterioration of CD4+ T-lymphocyte cell counts or progression of HIV disease has not been demonstrated among
HIV-infected persons after influenza vaccination compared with unvaccinated persons
(191,199). Limited information is available concerning the effect of antiretroviral therapy on increases in HIV RNA levels after either natural influenza virus infection
or influenza vaccination (181,200). Because influenza can result in serious illness and because vaccination with
inactivated influenza vaccine might result in the production of protective antibody titers, vaccination might benefit
HIV-infected persons, including HIV-infected pregnant women. Therefore, influenza vaccination is
The risk for exposure to influenza during travel depends on the time of year and destination. In the tropics, influenza
can occur throughout the year. In the temperate regions of the Southern Hemisphere, the majority of influenza
activity occurs during April--September. In temperate climate zones of the Northern and Southern Hemispheres, travelers also can
be exposed to influenza during the summer, especially when traveling as part of large organized tourist groups (e.g., on
cruise ships) that include persons from areas of the world where influenza viruses are circulating
(201,202). Persons at high risk for
complications of influenza and who were not vaccinated with influenza vaccine during the preceding fall or winter
should consider receiving influenza vaccine before travel if they plan to
travel to the tropics,
travel with organized tourist groups at any time of year, or
travel to the Southern Hemisphere during
No information is available regarding the benefits of revaccinating persons before summer travel who were
already vaccinated during the preceding fall. Persons at high risk who received the previous season's vaccine before travel should
be revaccinated with the current vaccine the following fall or winter. Persons aged
>50 years and persons at high risk
should consult with their health-care provider before embarking on travel during the summer to discuss the symptoms and risks
for influenza and other travel-related diseases.
In addition to the groups for which annual influenza vaccination is recommended, vaccination providers should
administer influenza vaccine to any person who wishes to reduce the likelihood of becoming ill with influenza or transmitting
influenza to others should they become infected (the vaccine can be administered to children aged
>6 months), depending on vaccine availability (see Influenza Vaccine Supply and Timing of Annual Influenza Vaccination). A strategy of universal
influenza vaccination is being assessed by ACIP.
Persons who provide essential community services should be considered for vaccination to minimize disruption of
essential activities during influenza outbreaks. Students or other persons in institutional settings (e.g., those who reside in
dormitories) should be encouraged to receive vaccine to minimize the disruption of routine activities during epidemics
Inactivated Influenza Vaccine Recommendations
Dosage recommendations vary according to age group (Table 4). Among previously unvaccinated children
aged 6 months--<9 years, 2 doses of inactivated vaccine administered
>1 month apart are recommended for eliciting
satisfactory antibody responses (85--88). If possible, the second dose should be administered before the onset of influenza season. If
a child aged 6 months--<9 years receiving influenza vaccine for the first time does not receive a second dose of vaccine
within the same season, only 1 dose of vaccine should be administered the following season. Two doses are not required at that
time. ACIP does not recommend that a child receiving influenza vaccine for the first time be administered the first dose of
vaccine in the spring as a priming dose for the following
Among adults, studies have indicated limited or no improvement in antibody response when a second dose is
administered during the same season
(204--206). Even when the current influenza vaccine contains one or more antigens administered
in previous years, annual vaccination with the vaccine is necessary because immunity declines during the year after
vaccination (207,208). Vaccine prepared for a previous influenza season should not be administered to provide protection for the
current season (see Persons Who Should Not Be Vaccinated with Inactivated Influenza Vaccine).
The intramuscular route is recommended for inactivated influenza vaccine. Adults and older children should be
vaccinated in the deltoid muscle. A needle length
>1 inch should be considered for these age groups because needles <1 inch might be
of insufficient length to penetrate muscle tissue in certain adults and older children
Infants and young children should be vaccinated in the anterolateral aspect of the thigh
(210). ACIP recommends a needle length of 7/8--1 inch for children aged <12 months for intramuscular vaccination into the anterolateral thigh. When
injecting into the deltoid muscle among children with adequate deltoid muscle mass, a needle length of 7/8--1.25 inches
is recommended (210).
TIV Side Effects and Adverse Reactions
When educating patients regarding potential side effects, clinicians should emphasize that 1) inactivated influenza
vaccine contains noninfectious killed viruses and cannot cause influenza, and 2) coincidental respiratory disease unrelated to
influenza vaccination can occur after vaccination.
TIV Local Reactions
In placebo-controlled studies among adults, the most frequent side effect of vaccination is soreness at the vaccination
site (affecting 10%--64% of patients) that lasts <2 days
(12,211--213). These local reactions typically are mild and rarely
interfere with the person's ability to conduct usual daily activities. One blinded, randomized, cross-over study among 1,952 adults
and children with asthma demonstrated that only body aches were reported more frequently after inactivated influenza
vaccine (25.1%) than placebo-injection (20.8%)
(214). One study reported 20%--28% of children with asthma aged 9
months--18 years experienced local pain and swelling
(81), and another study reported 23% of children aged 6 months--4 years
with chronic heart or lung disease had local reactions
(76). A different study reported no difference in local reactions among
53 children aged 6 months--6 years with high-risk medical conditions or among 305 healthy children aged 3--12 years in
a placebo-controlled trial of inactivated influenza vaccine
(77). In a study of 12 children aged 5--32 months, no
substantial local or systemic reactions were noted
(215). The interpretation of these findings should be made with caution given the
small number of children studied.
TIV Systemic Reactions
Fever, malaise, myalgia, and other systemic symptoms can occur after vaccination with inactivated vaccine and most
often affect persons who have had no previous exposure to the influenza virus antigens in the vaccine (e.g., young
children) (216,217). These reactions begin 6--12 hours after vaccination and can persist for 1--2 days. Placebo-controlled
trials demonstrate that among older persons and healthy young adults, administration of split-virus influenza vaccine is
not associated with higher rates of systemic symptoms (e.g.,
fever, malaise, myalgia, and headache) when compared with
placebo injections (12,211--213).
In a randomized cross-over study among both children and adults with asthma, no increase in asthma exacerbations
was reported for either age group (214). An analysis of 215,600 children aged <18 years and 8,476 children aged 6--23
months enrolled in one of five HMOs reported no increase in biologically plausible medically attended events during the 2
weeks after inactivated influenza vaccination, compared with control periods 3--4 weeks before and after vaccination
(218). In a study of 791 healthy children
(71), postvaccination fever was noted among 11.5% of children aged 1--5 years, among
4.6% of children aged 6--10 years, and among 5.1% of children aged 11--15 years. Among children with high-risk
medical conditions, one study of 52 children aged 6 months--4 years indicated that 27% had fever and 25% had irritability
and insomnia (76); another study among 33 children aged 6--18 months indicated that one child had irritability and one had
a fever and seizure after vaccination (219). No placebo comparison group was used in these studies.
A published review of the Vaccine Adverse Event Reporting System (VAERS) reports of TIV in children aged 6--23
months documented that the most frequently reported adverse events were fever, rash, injection-site reactions, and seizures.
The majority of the small total number of reported seizures appeared to be febrile
(220). Because of the limitations of
passive reporting systems, determining causality for specific types of adverse events, with the exception of
injection-site reactions, is usually not possible using VAERS data alone. A
population-based study of TIV safety in children aged 6--23 months
who were vaccinated during 1993--1999 indicated no
vaccine-associated adverse events that had a plausible
relationship to vaccination (221).
Health-care professionals should promptly report to VAERS all clinically significant adverse events after
influenza vaccination, even if the health-care professional is not certain that the vaccine caused the event. The Institute of Medicine
has specifically recommended reporting of potential neurologic complications (e.g., demyelinating disorders such as
Guillain-Barré syndrome [GBS]), although no evidence exists of a causal relation between influenza vaccine and neurologic
disorders in children.
Immediate, presumably allergic, reactions (e.g., hives, angioedema, allergic asthma, and systemic anaphylaxis) rarely
occur after influenza vaccination (222). These reactions probably result from hypersensitivity to certain vaccine components;
the majority of reactions probably are caused by residual egg protein. Although current influenza vaccines contain only a
quantity of egg protein, this protein can induce immediate hypersensitivity reactions among persons who have severe
egg allergy. Persons who have had hives or swelling of the lips or tongue or who have experienced acute respiratory distress
or collapse after eating eggs should consult a physician for appropriate evaluation to help determine if vaccine should
be administered. Persons who have documented immunoglobulin E (IgE)-mediated hypersensitivity to eggs, including
those who have had occupational asthma or other allergic responses to egg protein, might also be at increased risk for
allergic reactions to influenza vaccine, and consultation with a physician should be considered
(223--225). Persons with a history of severe hypersensitivity (e.g., anaphylaxis) to eggs should not receive influenza vaccine.
Hypersensitivity reactions to any vaccine component can occur theoretically. Although exposure to vaccines
containing thimerosal can lead to induction of hypersensitivity, the majority of patients do not have reactions to thimerosal when it
is administered as a component of vaccines, even when patch or intradermal tests for thimerosal indicate
hypersensitivity (226,227). When reported, hypersensitivity to thimerosal usually has consisted of local, delayed
hypersensitivity reactions (226).
GBS and TIV
The 1976 swine influenza vaccine was associated with an increased frequency of GBS
(228,229). Among persons who received the swine influenza vaccine in 1976, the rate of GBS was <10 cases/1 million persons vaccinated. The risk
for influenza vaccine-associated GBS was higher among persons aged
>25 years than persons aged <25 years
(228). Evidence for a causal relation of GBS with subsequent vaccines prepared from other influenza viruses is unclear. Obtaining
strong epidemiologic evidence for a possible limited increase in risk is difficult for such a rare condition as GBS, which has
an estimated annual incidence of 10--20 cases/1 million adults
Investigations to date have not documented a substantial increase in GBS associated with influenza vaccines (other than
the swine influenza vaccine in 1976), and suggest that, if influenza vaccine does pose a risk, it is probably slightly more than
one additional case/1 million persons vaccinated. During three of four influenza seasons studied during 1977--1991, the
overall relative risk estimates for GBS after influenza vaccination were slightly elevated, but they were not statistically significant
in any of these studies (231--233). However, in a study of the 1992--93 and 1993--94 influenza seasons, the overall relative
risk for GBS was 1.7 (CI = 1.0--2.8; p = 0.04) during the 6 weeks after vaccination, representing approximately 1 additional
case of GBS/1 million persons vaccinated; the combined number of GBS cases peaked 2
weeks after vaccination (234). VAERS has documented decreased reporting of postinfluenza vaccine GBS across age groups, despite overall increased reporting of other,
non-GBS conditions occurring after influenza vaccination
(235). Cases of GBS after influenza infection have been reported, but
no other epidemiologic studies have documented such an association
(236,237). Substantial evidence exists that several
infectious illnesses, most notably Campylobacter
jejuni and upper respiratory tract infections are associated with GBS
Even if GBS were a true side effect of vaccination in the years other than 1976, the estimated risk for GBS of
approximately 1 additional case/1 million persons vaccinated is substantially less than the risk for severe influenza, which can be
prevented by vaccination among all age groups, especially persons aged
>65 years and those who have medical indications for
influenza vaccination (Table 1) (see Hospitalizations and Deaths from Influenza). The potential benefits of influenza vaccination
in preventing serious illness, hospitalization, and death substantially outweigh the possible risks for experiencing
vaccine-associated GBS. The average case fatality ratio for GBS is 6% and increases with age
(230,241). No evidence indicates that the case fatality ratio for GBS differs among vaccinated persons and those not vaccinated.
The incidence of GBS among the general population is low, but persons with a history of GBS have a substantially
greater likelihood of subsequently experiencing GBS than persons without such a history
(231,242). Thus, the likelihood of coincidentally experiencing GBS after influenza vaccination is expected to be greater among persons with a history of
GBS than among persons with no history of this syndrome. Whether influenza vaccination specifically might increase the risk
for recurrence of GBS is unknown. However, avoiding vaccinating persons who are not at high risk for severe
influenza complications and who are known to have experienced GBS within 6 weeks after a previous influenza vaccination is
prudent. As an alternative, physicians might consider using influenza antiviral chemoprophylaxis for these persons. Although data
are limited, for the majority of persons who have a history of GBS and who are at high risk for severe complications
from influenza, the established benefits of influenza vaccination justify yearly vaccination.
Thimerosal and Inactivated Influenza Vaccine
Thimerosal, a mercury-containing compound, has been used as a preservative in vaccines since the 1930s and is used
in multidose vials of inactivated influenza vaccine to reduce the likelihood of bacterial contamination
(243). Many of the single-dose syringes and vials of TIV are thimerosal-free or contain only trace amounts of thimerosal
(Table 4). No scientific evidence indicates that thimerosal in vaccines, including influenza vaccines, leads to serious adverse events in
vaccine recipients (244). However, in 1999, the U.S.
Public Health Service and other organizations recommended that efforts
be made to eliminate or reduce the thimerosal content in vaccines to decrease total mercury exposure, chiefly among
infants (243--245). Since mid-2001, vaccines routinely recommended for infants in the United States have been manufactured
either without or with only trace amounts of thimerosal, resulting in a substantial reduction in the total mercury exposure
from vaccines for children (210). Vaccines containing trace amounts of thimerosal have <1 mcg
The risks for severe illness from influenza virus infection are elevated among both young children and pregnant
women, and persons in both groups benefit from vaccination. In contrast, no scientifically conclusive evidence exists of harm
from exposure to thimerosal preservative-containing vaccine. In fact, evidence is accumulating that supports the absence of
any harm resulting from exposure to such vaccines
(243,246--248). Therefore, the benefits of influenza vaccination outweigh
the theoretical risk, if any, from thimerosal exposure through vaccination. Nonetheless, certain persons remain
concerned regarding exposure to thimerosal. As of February 2006, six states had enacted legislation banning the administration
of vaccines containing mercury; the provisions defining mercury content vary. These laws might present a barrier to
vaccination until sufficient numbers of doses of influenza vaccines without thimerosal as a preservative or in trace amounts are available.
The U.S. vaccine supply for infants and pregnant women is in a period of transition; the availability of
thimerosal-reduced or thimerosal-free vaccine intended for these groups is being expanded by manufacturers as a feasible means
of reducing an infant's total exposure to mercury, because other environmental sources of exposure are more difficult
or impossible to eliminate. Reductions in thimerosal in other vaccines have been achieved already and have resulted
in substantially lowered cumulative exposure to thimerosal from vaccination among infants and children. For all of
those reasons, persons for whom inactivated influenza vaccine is recommended may receive vaccine with or without
thimerosal, depending on availability.
Persons Who Should Not Be Vaccinated with Inactivated Influenza Vaccine
Inactivated influenza vaccine should not be administered to persons known to have anaphylactic hypersensitivity to eggs
or to other components of the influenza vaccine without first consulting a physician (see Side Effects and Adverse
Reactions). Chemoprophylactic use of antiviral agents is an option for preventing influenza among such persons. However, persons
who have a history of anaphylactic hypersensitivity to vaccine components but who also are at high risk for complications
from influenza can benefit from vaccine after appropriate allergy evaluation and desensitization. Information regarding
vaccine components is located in package inserts from each manufacturer. Persons with moderate-to-severe acute febrile illness
usually should not be vaccinated until their symptoms have abated. However, minor illnesses with or without fever do
not contraindicate use of influenza vaccine, particularly among children with mild upper-respiratory tract infection or
TIV and Use of Influenza Antiviral Medications
As TIV contains only influenza virus subunits and no live virus, no contraindication exists to the coadministration of
TIV and influenza antivirals (see sections on Chemoprophylaxis; and Control of Influenza Outbreaks in Institutions).
LAIV is an option for vaccination of healthy, nonpregnant persons aged 5--49 years who want to avoid influenza, and
those who might be in close contact with persons at high risk for severe complications, including health-care workers.
During periods when inactivated vaccine is in short supply, use of LAIV is encouraged when feasible for eligible persons
(including health-care workers) because use of LAIV by these persons might increase availability of inactivated vaccine for persons
groups at high risk. Possible advantages of LAIV include its potential to induce a broad mucosal and systemic
immune response, its ease of administration, and the acceptability of an intranasal rather than intramuscular route of administration.
LAIV Dosage and Administration
LAIV is intended for intranasal administration only and should not be administered by the intramuscular, intradermal,
or intravenous route. LAIV must be thawed before administration. This can be accomplished by holding an individual
sprayer in the palm of the hand until thawed, with subsequent immediate administration. Alternatively, the vaccine can be thawed
in a refrigerator and stored at
<60 hours before use. Vaccine should not be refrozen after thawing. LAIV is
supplied in a prefilled single-use sprayer containing 0.5 mL of vaccine. Approximately 0.25 mL (i.e., half of the total sprayer
contents) is sprayed into the first nostril while the recipient is in the upright position. An attached dose-divider clip is removed
from the sprayer to administer the second half of the dose into the other nostril. If the vaccine recipient sneezes
after administration, the dose should not be repeated.
LAIV should be administered annually according to the following schedule:
Children aged 5--<9 years previously unvaccinated at any time with either LAIV or inactivated influenza vaccine
should receive 2 doses* of LAIV separated by 6--10 weeks; if possible, the second dose of vaccine should be administered
before the onset of influenza season.
Children aged 5--<9 years previously vaccinated at any time with either LAIV or inactivated influenza vaccine should
receive 1 dose of LAIV. They do not require a second dose.
Persons aged 9--49 years should receive 1 dose of LAIV.
LAIV can be administered to persons with minor acute illnesses (e.g., diarrhea or mild upper respiratory tract
infection with or without fever). However, if clinical judgment indicates nasal congestion is present that might impede delivery of
the vaccine to the nasopharyngeal mucosa, deferral of administration should be considered until resolution of the
Whether concurrent administration of LAIV with other vaccines affects the safety or efficacy of either LAIV or
the simultaneously administered vaccine is unknown. In the absence of specific data indicating interference, following the
ACIP general recommendations for immunization is prudent
(210). Inactivated vaccines do not interfere with the immune
response to other inactivated vaccines or to live vaccines. Inactivated or live vaccines can be administered simultaneously
with LAIV. However, after administration of a live vaccine, at least 4 weeks should pass before another live vaccine is administered
(see Persons Who Should Not Be Vaccinated with LAIV).
LAIV and Use of Influenza Antiviral Medications
The effect on safety and efficacy of LAIV coadministration with influenza antiviral medications has not been
studied. However, because influenza antivirals reduce replication of influenza viruses, LAIV should not be administered until 48
hours after cessation of influenza antiviral therapy, and influenza antiviral medications should not be administered for 2 weeks
after receipt of LAIV.
LAIV must be stored at -15ºC or colder. A manufacturer-supplied freezer box was formerly required for storage of LAIV in
a frost-free freezer; however, the freezer box is now optional, and LAIV may now be stored in frost-free freezers without using
a freezer box. LAIV can be thawed in a refrigerator and stored at
<60 hours before use. It should not be refrozen
after thawing because of decreased vaccine potency.
Shedding, Transmission, and Stability of Vaccine Viruses
Available data indicate that both children and adults vaccinated with LAIV can shed vaccine viruses for
>2 days after vaccination, although in lower titers than typically occur with shedding of wild-type influenza viruses. Shedding should
not be equated with person-to-person transmission of vaccine viruses, although, in rare instances, shed vaccine viruses can
be transmitted from vaccinees to nonvaccinated persons.
One unpublished study of a child care center setting
assessed transmissibility of vaccine viruses from 98 vaccinated to
99 unvaccinated children, all aged 8--36 months. Eighty percent of vaccine recipients shed one or more virus strains, with
a mean of 7.6 days' duration (249). One vaccine type influenza type B isolate was recovered from a placebo recipient and
was confirmed to be vaccine-type virus. The type B isolate retained the cold-adapted, temperature-sensitive,
phenotype, and it possessed the same genetic sequence as a virus shed from a vaccine recipient in the same children's
play group. The placebo recipient from whom the influenza type B vaccine virus was isolated did not exhibit symptoms that
were different from those experienced by vaccine recipients. The estimated probability of acquiring vaccine virus after close
contact with a single LAIV recipient in this child care population was 0.58%--2.4%.
One study assessing shedding of vaccine viruses in 20 healthy vaccinated adults aged 18--49 years demonstrated that
the majority of shedding occurred within the first 3 days after vaccination, although one participant was noted to shed
virus on day 7 after vaccine receipt. No study participants shed vaccine viruses
>10 days after vaccination. Duration or type
of symptoms associated with receipt of LAIV did not correlate with duration of shedding vaccine viruses.
Person-to-person transmission of vaccine viruses was not assessed in this study
Another study assessing shedding of vaccine viruses in 14 healthy adults aged 18--49 years indicated that 50% of these
adults had viral antigen detected by direct immunofluorescence or rapid antigen tests within 7 days of vaccination.
The majority of viral shedding was detected on day 2 or 3.
Person-to-person transmission of vaccine viruses was not assessed in this study
In clinical trials, viruses shed by vaccine recipients have been phenotypically stable. In one study, nasal and throat
swab specimens were collected from 17 study participants for 2 weeks after vaccine receipt
(252). Virus isolates were analyzed by multiple genetic techniques. All isolates retained the LAIV genotype after replication in the human host, and all retained
the cold-adapted and temperature-sensitive phenotypes. A study conducted in a day care setting found that limited
genetic change occurred in the LAIV strains after replication in the vaccine recipients
LAIV Side Effects and Adverse Reactions
Twenty prelicensure clinical trials assessed the safety of the approved LAIV. In these combined studies,
approximately 28,000 doses of the vaccine were administered to approximately 20,000 persons. A subset of these trials were
randomized, placebo-controlled studies in which an estimated 4,000 healthy children aged 5--17 years and 2,000 healthy adults aged
18--49 years were vaccinated. The incidence of adverse events possibly complicating influenza (e.g., pneumonia,
bronchitis, bronchiolitis, or central nervous system events) was not statistically different among LAIV and placebo recipients aged
5--49 years. LAIV is made from attenuated viruses and does not cause influenza in vaccine recipients.
Children. In a subset of healthy children aged 60--71 months from one clinical trial
(111,112), certain signs and symptoms were reported more often among LAIV recipients after the first dose (n = 214) than placebo recipients (n = 95) (e.g.,
runny nose, 48.1% versus 44.2%; headache, 17.8% versus 11.6%; vomiting, 4.7% versus 3.2%; and myalgias, 6.1% versus
4.2%), but these differences were not statistically significant. In other trials, signs and symptoms reported after LAIV
administration have included runny nose or nasal congestion (20%--75%), headache (2%--46%), fever (0--26%), vomiting
(3%--13%), abdominal pain (2%), and myalgias (0--21%)
(105,108,110,254--256). These symptoms were associated more often with
the first dose and were self-limited. Data from a study of children aged 1--17 years indicated an increase in asthma or
reactive airways disease in the subset aged 1--<5 years
(257,258). Because of these data, LAIV is not approved for use among
children aged <5 years. Another study was conducted among more than 11,000 children aged 18 months--18 years in which
18,780 doses of vaccine were administered over a 4-year period. This study did not observe an increase in asthma visits 0--15
days after vaccination for children who were aged 18 months--4 years compared with the prevaccination period; however,
a significant increase in asthma events was observed 15--42 days after vaccination but only in vaccine year 1
Adults. Among adults, runny nose or nasal congestion (28%--78%), headache (16%--44%), and sore throat
(15%--27%) have been reported more often among vaccine recipients than placebo recipients
(114,260,261). In one clinical trial
(114) among a subset of healthy adults aged 18--49 years, signs and symptoms reported more frequently among LAIV recipients
(n = 2,548) than placebo recipients (n = 1,290) within 7 days after each dose included cough (13.9% versus 10.8%), runny
nose (44.5% versus 27.1%), sore throat (27.8% versus 17.1%), chills (8.6% versus 6.0%), and
tiredness/weakness (25.7% versus 21.6%).
Safety Among Groups at High Risk from
Influenza-Related Morbidity. Until additional data are acquired and
analyzed, persons at high risk for experiencing complications from influenza virus infection (e.g., immunocompromised
patients; patients with asthma, cystic fibrosis, or chronic obstructive pulmonary disease; or persons aged
>65 years) should not be vaccinated with LAIV. Protection from influenza among these groups should be accomplished using inactivated
Serious Adverse Events. Serious adverse events requiring medical attention among healthy children aged 5--17 years
or healthy adults aged 18--49 years occurred at a rate of <1%. Surveillance will continue for adverse events that might not
been detected in previous studies. Reviews of reports to VAERS after vaccination of approximately 2,500,000 persons
during the 2003--04 and 2004--05 influenza seasons did not reveal any substantial new safety concerns
(262,263). Health-care professionals should promptly report all clinically significant adverse events after LAIV administration to VAERS,
as recommended for inactivated influenza vaccine.
Persons Who Should Not Be Vaccinated with LAIV
The following populations should not be vaccinated with LAIV:
persons aged <5 years or those aged
persons with asthma, reactive airways disease, or other chronic disorders of the pulmonary or cardiovascular
systems; persons with other underlying medical conditions, including such metabolic diseases as diabetes, renal dysfunction,
and hemoglobinopathies; or persons with known or suspected immunodeficiency diseases or who are
receiving immunosuppressive therapies;
children or adolescents receiving aspirin or other salicylates (because of the association of Reye syndrome with
wild-type influenza virus infection);
persons with a history of GBS;
pregnant women; or
persons with a history of hypersensitivity, including anaphylaxis, to any of the components of LAIV or to eggs.
Vaccination of Close Contacts of Persons at High Risk for Complications from Influenza
Close contacts of persons at high risk for complications from influenza should receive influenza vaccine to
reduce transmission of wild-type influenza viruses to persons at high risk. Use of inactivated influenza vaccine is preferred
for vaccinating household members, health-care workers, and others who have close contact with severely
immunocompromised persons (e.g., patients with hematopoietic stem cell transplants) during those periods in which the
immunocompromised person requires care in a protective environment. The rationale for not using LAIV among health-care workers caring for
such patients is the theoretical risk that a live, attenuated vaccine virus could be transmitted to the severely
immunocompromised person. If a health-care worker receives LAIV, that worker should refrain from contact with severely
immunocompromised patients for 7 days after vaccine receipt. Hospital visitors who have received LAIV should refrain from contact with
severely immunocompromised persons for 7 days after vaccination; however, such persons need not be excluded from visitation
of patients who are not severely immunocompromised. ACIP has not indicated a preference for inactivated influenza vaccine
use by health-care workers or other persons who have close contact with persons with
lesser degrees of immunodeficiency (e.g., persons with diabetes, persons with asthma taking corticosteroids, or persons infected with HIV) or for inactivated
influenza vaccine use by health-care workers or other healthy persons aged 5--49 years in close contact with all other groups at
Personnel Who May Administer LAIV
Low-level introduction of vaccine viruses into the environment is likely unavoidable when administering LAIV. The risk
for acquiring vaccine viruses from the environment is unknown but likely to be limited. Severely immunocompromised
persons should not administer LAIV. However, other persons at high risk for influenza complications may administer LAIV.
These include persons with underlying medical conditions placing them at high risk or who are likely to be at risk,
including pregnant women, persons with asthma, and persons aged
Recommended Vaccines for Different Age Groups
When vaccinating children aged 6 months--3 years, health-care providers should use inactivated influenza vaccine that
has been approved by FDA for this age group. Inactivated influenza vaccine from sanofi pasteur (Fluzone) is approved for
use among persons aged >6 months. Inactivated influenza vaccine from Novartis, formerly Chiron (Fluvirin), is labeled in
the United States for use among persons aged
>4 years because data to demonstrate efficacy among younger persons have
not been provided to FDA, whereas inactivated influenza vaccine from GlaxoSmithKline (FLUARIX) is labeled for use in
persons aged >18 years. LAIV from MedImmune (FluMist) is approved for use by healthy persons aged 5--49 years (Table 4).
Influenza Vaccine Supply and Timing of Annual Influenza Vaccination
The annual supply of influenza vaccine and the timing of its distribution cannot be guaranteed in any year.
Currently, influenza vaccine manufacturers are projecting that approximately 100 million doses of influenza vaccine will be available
in the United States for the 2006--07 influenza season, an amount that is approximately 16% more doses than were available
for the 2005--06 season. An additional 15 million--20 million doses might be available if a new vaccine is licensed in
2006. (Information about the status of licensure of new vaccines is available at
http://aapredbook.aappublications.org/news/vaccstatus.pdf.) However, influenza vaccine distribution delays or vaccine shortages remain possible in part because of
the inherent critical time constraints in manufacturing the vaccine given the annual updating of the influenza vaccine strains.
To ensure optimal use of available doses of influenza vaccine, health-care providers, those planning organized campaigns,
and state and local public health agencies should
1) develop plans for expanding outreach and infrastructure to vaccinate more persons than last year and
2) develop contingency plans for the timing and prioritization of administering influenza vaccine, if the supply of vaccine
is delayed and/or reduced.
CDC and other public health agencies will assess the vaccine supply on a continuing basis throughout the
manufacturing period and will inform both providers and the general public if a substantial delay or an inadequate supply occurs.
Because LAIV is approved for use in healthy persons aged 5--49 years, no recommendations exist for limiting the timing
and prioritization of administering LAIV. Administration of LAIV is encouraged as soon as it is available and throughout
If the supply of inactivated influenza vaccine is adequate and a sufficient number of doses will be available beginning
in September, vaccination efforts should be structured to ensure the vaccination of as many persons as possible over the course
of several months. Even if vaccine distribution begins in September, distribution probably will not be completed until
December or January; therefore, the following recommendations reflect this phased distribution during the months of
October, November, and December, and possibly later. The prioritized (tiered) use of influenza vaccine during inactivated
influenza vaccine shortages applies only to the use of inactivated vaccine and not to LAIV. When feasible, during shortages
of inactivated influenza vaccine, LAIV should be used preferentially for all healthy persons aged 5--49 years (including
health-care workers) to increase the availability of inactivated vaccine for groups at high risk.
The following section provides guidance regarding the timing of vaccination under two scenarios: 1) if the supply
of inactivated influenza vaccine is adequate, and 2) if a reduced or delayed supply of inactivated vaccine occurs.
To avoid missed opportunities for vaccination of persons at increased risk for serious complications and their
household contacts (including out-of-home caregivers and household contacts of children aged 0--59 months), such persons should
be offered vaccine beginning in September during routine health-care visits or during hospitalizations, if vaccine is
available. However, in facilities housing older persons (e.g., nursing homes), vaccination before October typically should be
avoided because antibody levels in such persons can begin to decline more rapidly after vaccination
(264). If vaccine supplies are sufficient, vaccination of other persons also may begin before October.
In addition, because children aged 6 months--<9 years who have not been previously vaccinated need 2 doses of
vaccine, they should receive their first dose in September, if vaccine is available, so that both doses can be administered before
the onset of influenza activity. For previously vaccinated children, only 1 dose is needed.
Vaccination in October and November
The optimal time for vaccination efforts is usually during October--November. In October, vaccination in
provider-based settings should start or continue for all patients---both high risk and healthy---and extend throughout November.
Vaccination of children aged 6 months--<9 years who are receiving vaccine for the first time should also begin in October, if not
done earlier, because those children need a booster dose 4--10 weeks after the initial dose, depending upon whether they
are receiving inactivated influenza vaccine or LAIV.
If supplies of inactivated influenza vaccine are not adequate, ACIP recommends that vaccine providers focus
their vaccination efforts in October, primarily on persons aged
>50 years, persons aged <50 years at increased risk for
influenza-related complications (including children aged 6--59 months), household contacts of persons at high risk (including
out-of-home caregivers and household contacts of children aged 0--59 months), and health-care workers
(178). Efforts to vaccinate other persons who wish to decrease their risk for influenza virus infection should not begin until November; however, if
such persons request vaccination in October, vaccination should not be deferred, unless vaccine supplies dictate otherwise.
Vaccination in December and Later
When inactivated vaccine is delayed, a substantial proportion of doses often do not become available until December
or later. Nevertheless, even when supply is not delayed or reduced, as demonstrated by the relatively low vaccination
coverage levels among persons in the defined priority groups, many persons who should receive influenza vaccine remain
unvaccinated (Table 3).
Providers should routinely offer influenza vaccine throughout the influenza season even after influenza activity has
been documented in the community. In the United States, seasonal influenza activity can begin to increase as early as October
or November, but influenza activity has not reached peak levels until late December--early March in the majority of
recent seasons (Table 5). Although the timing of influenza activity can vary by region, vaccine administered after November is
likely to be beneficial in the majority of influenza seasons. Adults have peak antibody protection against influenza virus infection
2 weeks after vaccination (265,266).
Timing of Organized Vaccination Campaigns
Persons and institutions planning substantial organized vaccination campaigns (e.g., health departments,
occupational health clinics, and community vaccinators) should consider scheduling these events after at least mid-October because
the availability of vaccine in any location cannot be ensured consistently in early fall. Scheduling campaigns after
mid-October will minimize the need for cancellations because vaccine is unavailable. These vaccination clinics should be scheduled
through November, with attention to settings that serve children aged 6--59 months, pregnant women, other persons aged <50 years
at increased risk for influenza-related complications, persons aged
>50 years, health-care workers, and household contacts
and out-of-home caregivers of persons at high risk (including children aged 0--59 months) to the extent feasible. Planners
are encouraged to schedule at least one vaccination clinic in December.
During a vaccine shortage or delay, substantial proportions of inactivated influenza vaccine doses may not be released
until November and December or later. Beginning in
November, vaccination campaigns can be broadened to include
healthy persons who wish to reduce their risk for influenza virus infection. ACIP recommends organizers schedule these
vaccination clinics throughout November and December. When the vaccine is significantly delayed, agencies should consider
offering vaccination clinics into January as long as vaccine supplies are available. Campaigns using LAIV are optimally conducted
in October and November but can also extend into January.
Strategies for Implementing Vaccination Recommendations in
Successful vaccination programs combine publicity and education for health-care workers and other potential
vaccine recipients, a plan for identifying persons at high risk, use of reminder/recall systems, assessment of practice-level
vaccination rates with feedback to staff, and efforts to remove administrative and financial barriers that prevent persons from receiving
the vaccine, including use of standing orders programs
(19,267). Since October 2005, the Centers for
Medicare and Medicaid Services (CMS) has required nursing homes participating in the Medicare and Medicaid programs to offer all
residents influenza and pneumococcal vaccines and to document the results. According to the requirements, each resident is to
be vaccinated unless it is medically contraindicated or the resident or his/her legal representative refuses vaccination.
This information is to be reported as part of the CMS Minimum Data Set, which tracks nursing home health parameters
The use of standing orders programs by long-term--care facilities (e.g., nursing homes and skilled nursing
facilities), hospitals, and home health agencies might help to ensure the administration of recommended vaccinations for adults
(269). Standing orders programs for both influenza and pneumococcal vaccination should be conducted under the supervision of
a licensed practitioner according to a physician-approved facility or agency policy by health-care workers trained to
patients for contraindications to vaccination, administer vaccine, and monitor for adverse events. CMS has removed
the physician signature requirement for the administration of influenza and pneumococcal vaccines to Medicare and
Medicaid patients in hospitals, long-term--care facilities, and home health agencies
(269). To the extent allowed by local and state
law, these facilities and agencies may implement standing orders for influenza and pneumococcal vaccination of Medicare-
and Medicaid-eligible patients. Other settings (e.g., outpatient facilities, managed care organizations, assisted living
facilities, correctional facilities, pharmacies, and adult workplaces) are encouraged to introduce standing orders programs as well
(20). In addition, physician reminders (e.g., flagging charts) and patient reminders are recognized strategies for increasing rates
of influenza vaccination. Persons for whom influenza vaccine is recommended can be identified and vaccinated in the
settings described in the following sections.
Outpatient Facilities Providing Ongoing Care
Staff in facilities providing ongoing medical care (e.g., physicians' offices, public health clinics, employee health
clinics, hemodialysis centers, hospital specialty-care clinics, and outpatient rehabilitation programs) should identify and label
the medical records of patients who should receive vaccination. Vaccine should be offered during visits beginning
in September (if vaccine is available) and throughout the influenza season. The offer of vaccination and its receipt or
refusal should be documented in the medical record. Patients for whom vaccination is recommended and who do not have
regularly scheduled visits during the fall should be reminded by mail, telephone, or other means of the need for vaccination.
Outpatient Facilities Providing Episodic or Acute Care
Beginning each September, acute health-care facilities (e.g., emergency departments and walk-in clinics) should
offer vaccinations to persons for whom vaccination is recommended or provide written information regarding why, where,
and how to obtain the vaccine. This written information should be available in languages appropriate for the populations
served by the facility.
Nursing Homes and Other Residential Long-Term--Care Facilities
During October and November each year, vaccination should be routinely provided to all residents of chronic-care
facilities with the concurrence of attending physicians. Consent for vaccination should be obtained from the resident or a
family member at the time of admission to the facility or anytime afterwards. Ideally, all residents should be vaccinated at one
time, before influenza season. Residents admitted through March after completion of the vaccination program at the facility
should be vaccinated at the time of admission.
Persons of all ages (including children) with high-risk conditions and persons aged
>50 years who are hospitalized at any time during September--March should be offered and strongly encouraged to receive influenza vaccine before they
are discharged if they have not already received the vaccine during that season. In one study, 39%--46% of adult
patients hospitalized during the winter with influenza-related diagnoses had been hospitalized during the preceding fall
(270). Thus, the hospital serves as a setting in which persons at increased risk for subsequent hospitalization can be identified
and vaccinated. However, vaccination of persons at high risk during or after their hospitalizations is often not done. In a study
of hospitalized Medicare patients, only 31.6% were vaccinated before admission, 1.9% during admission, and 10.6%
after admission (271). Using standing orders in hospitals increases vaccination rates among hospitalized persons
Visiting Nurses and Others Providing Home Care to Persons at High Risk
Beginning in September, nursing-care plans should identify patients for whom vaccination is recommended, and
vaccine should be administered in the home, if necessary. Caregivers and other persons in the household (including children)
should be referred for vaccination.
Other Facilities Providing Services to Persons Aged
Beginning in October, such facilities as assisted living housing, retirement communities, and recreation centers should
offer unvaccinated residents and attendees vaccination on-site before the start of the influenza season. Staff education
should emphasize the need for influenza vaccine.
Beginning in October each year, health-care facilities should offer influenza vaccinations to all workers, including night
and weekend staff. Particular emphasis should be placed on providing vaccinations to persons who care for members of groups
at high risk. Efforts should be made to educate health-care workers regarding the benefits of vaccination and the potential
health consequences of influenza illness for their patients, themselves, and their family members. All health-care workers should
be provided convenient access to influenza vaccine at the work site, free of charge, as part of employee health
Future Directions for Research and Recommendations Related to Influenza Vaccine
The relatively low effectiveness of influenza vaccine administered to older adults highlights the need for
more immunogenic influenza vaccines for the elderly
(273) and the need for additional research to understand potential biases
in estimating the benefits of vaccination among older adults in reducing hospitalizations and deaths
(274--276).Additional studies of the relative cost-effectiveness and cost utility of influenza vaccination among children and adults, especially
those aged <65 years, are needed and should be designed to account for year-to-year variations in influenza attack rates,
illness severity, hospitalization costs and rates, and vaccine effectiveness
(277). Additional data also are needed to quantify
the benefits of influenza vaccination of health-care workers in protecting their patients
(278). Furthermore, larger consortia of networks are needed that are able to assess rare events that occur after vaccination, including GBS.
ACIP continues to review new vaccination strategies to protect against influenza, including the possibility of
expanding routine influenza vaccination recommendations toward universal vaccination or other approaches that will help greatly reduce
or prevent the transmission of influenza
(279--282). In addition, as noted by the National Vaccine Advisory
Committee, strengthening the U.S. influenza vaccination system will require improving vaccine
financing, increasing demand, and implementing systems to help better understand the burden of influenza in the United States
(283). Strategies to evaluate the effect of vaccination recommendations remain critical.
Recommendations for Using Antiviral Agents for Influenza
Although annual vaccination is the primary strategy for preventing complications of influenza virus infections,
antiviral medications with activity against influenza viruses can be effective for the chemoprophylaxis and treatment of influenza.
Four licensed influenza antiviral agents are available in the United States: amantadine, rimantadine, zanamivir, and
oseltamivir. Influenza A virus resistance to amantadine and rimantadine can emerge rapidly during treatment. On the basis of
antiviral testing results conducted at CDC and in Canada indicating high levels of resistance
(23,24,284), ACIP recommends that neither amantadine nor rimantadine be used for the treatment or chemoprophylaxis of influenza A in the United States
until susceptibility to these antiviral medications has been re-established among circulating influenza A viruses. Oseltamivir
or zanamivir can be prescribed if antiviral treatment of influenza is indicated. Oseltamivir is approved for treatment of
persons aged >1 year, and zanamivir is approved for treatment of persons aged
>7 years. Oseltamivir and zanamivir can be used
for chemoprophylaxis of influenza; oseltamivir is licensed for use in persons aged
>1 year, and zanamivir is licensed for use
in persons aged >5 years.
Antiviral Agents for Influenza
Zanamivir and oseltamivir are chemically related antiviral drugs known as neuraminidase inhibitors that have
activity against both influenza A and B viruses. Both zanamivir and oseltamivir were approved in 1999 for treatment
of uncomplicated influenza virus infections. In 2000, oseltamivir was approved for chemoprophylaxis of influenza
among persons aged >13 years and was approved for chemoprophylaxis of children aged
>1 year in 2005. In 2006, zanamivir was approved for chemoprophylaxis of children aged
The two drugs differ in pharmacokinetics, side effects, routes of administration, approved age groups, dosages, and
costs. An overview of the indications, use, administration, and known primary side effects of these medications is presented in
the following sections. Package inserts should be consulted for additional information. Detailed information
regarding amantadine and rimantadine is available in the previous publication of the ACIP influenza recommendations
Role of Laboratory Diagnosis
Appropriate treatment of patients with respiratory illness depends on accurate and timely diagnosis. Influenza
surveillance information and diagnostic testing can aid clinical judgment and help guide treatment decisions. For example, early diagnosis
of influenza can reduce the inappropriate use of antibiotics and provide the option of using antiviral therapy. However,
because certain bacterial infections can produce symptoms similar to influenza, bacterial infections should be considered
and appropriately treated, if suspected. In addition, bacterial infections can occur as a complication of
The accuracy of clinical diagnosis of influenza on the basis of symptoms alone is limited because symptoms from
illness caused by other pathogens can overlap considerably with influenza
(33,42,43). Because testing all patients who might
have influenza is not feasible, influenza surveillance by state and local health departments and CDC can provide
information regarding the presence of influenza viruses in the community. Surveillance also can identify the predominant
circulating types, influenza A subtypes, and strains of influenza viruses.
Diagnostic tests available for influenza include viral culture, serology, rapid antigen testing, polymerase chain
reaction (PCR), and immunofluorescence assays
(28). The sensitivity and specificity of any test for influenza can vary by
the laboratory that performs the test, the type of test used, the type of specimen tested, and the timing of specimen
collection. Among respiratory specimens for viral isolation or rapid detection, nasopharyngeal specimens are typically more
effective than throat swab specimens (286). As with any diagnostic test, results should be evaluated in the context of other clinical
and epidemiologic information available to health-care providers.
Commercial rapid diagnostic tests are available that can detect influenza viruses in 30 minutes
(28,287). Some tests are approved for use in any outpatient setting, whereas others must be used in a moderately complex clinical laboratory.
These rapid tests differ in the types of influenza viruses they can detect and whether they can distinguish between influenza
types. Different tests can detect 1) only influenza A viruses; 2) both influenza A and B viruses, but not distinguish between the
two types; or 3) both influenza A and B and distinguish between the two.
None of the rapid tests provide any information regarding influenza A subtypes. The types of specimens acceptable for
use (i.e., throat, nasopharyngeal, or nasal; and aspirates, swabs, or washes) also vary by test. The specificity and, in particular,
the sensitivity of rapid tests are lower than for viral culture and vary by test
(288,289). Because of the lower sensitivity of
the rapid tests, physicians should consider confirming negative tests with viral culture or other means because of the possibility
of false-negative rapid test results, especially during periods of peak community influenza activity. In contrast,
false-positive rapid test results are less likely but can occur during periods of low influenza activity. Therefore, when interpreting results of
a rapid influenza test, physicians should consider the positive and negative predictive values of the test in the context of
the level of influenza activity in their community. Package inserts and the laboratory performing the test should be consulted
for more details regarding use of rapid diagnostic tests. Additional information concerning diagnostic testing is available at
Despite the availability of rapid diagnostic tests, collecting clinical specimens for viral culture is critical because only
culture isolates can provide specific information regarding circulating strains and subtypes of influenza viruses. This information
is needed to compare current circulating influenza strains with vaccine strains, to guide decisions regarding influenza
treatment and chemoprophylaxis, and to formulate vaccine for the coming year. Virus isolates also are needed to monitor the
emergence of antiviral resistance and the emergence of novel influenza A subtypes that might pose a pandemic threat.
Antiviral Drug-Resistant Strains of Influenza Virus
CDC recently reported that 193 (92%) of 209 influenza A (H3N2) viruses isolated from patients in 26 states
demonstrated a change at amino acid 31 in the M2 gene that confers resistance to adamantanes
(23,24). In addition, two of eight
influenza A (H1N1) viruses tested were resistant
(24). Canadian health authorities also have reported the same mutation in
a comparable proportion of isolates recently tested
(284). Until these findings, previous screenings of epidemic strains
of influenza A viruses found few amantadine- and rimantadine-resistant viruses
Viral resistance to adamantanes can emerge rapidly during treatment because a single point mutation at amino
acid positions 26, 27, 30, 31, or 34 of the M2 protein can confer cross resistance to both amantadine and rimantadine
(293,294). Drug-resistant viruses can emerge in approximately one third of patients when either amantadine or rimantadine is used
for therapy (293,295,296). During the course of amantadine or rimantadine therapy, resistant influenza strains can
susceptible strains within 2--3 days of starting therapy
(290,297). Resistant viruses have been isolated from persons who
live at home or in an institution in which other residents are taking or have taken amantadine or rimantadine as
therapy (298,299); however, the frequency with which resistant viruses are transmitted and their effect on efforts to control
influenza are unknown.
Persons who have influenza A virus infection and who are treated with either amantadine or rimantadine can shed
susceptible viruses early in the course of treatment and later shed drug-resistant viruses, including after 5--7 days of therapy
Resistance to zanamivir and oseltamivir can be induced in influenza A and B viruses in vitro
(300--307), but induction of resistance usually requires multiple passages in cell culture. By contrast, resistance to amantadine and rimantadine in vitro
can be induced with fewer passages in cell culture
(308,309). Development of viral resistance to zanamivir and oseltamivir
during treatment has been identified but does not appear to be frequent
(310--314). In one pediatric study, 5.5% of patients
treated with oseltamivir had posttreatment isolates that were resistant to neuraminidase inhibitors. One small study of
Japanese children treated with oseltamivir reported a high frequency of resistant viruses
(315). However, no transmission of neuraminidase inhibitor-resistant viruses in humans has been documented to date. No isolates with reduced susceptibility
to zanamivir have been reported from clinical trials, although the number of posttreatment isolates tested is limited
(316), and the risk for emergence of
zanamivir-resistant isolates cannot be quantified
(317). Only one clinical isolate with
reduced susceptibility to zanamivir, obtained from an immunocompromised child on prolonged therapy,
has been reported (312). Available diagnostic tests are not optimal for detecting clinical resistance to the neuraminidase inhibitor antiviral drugs,
and additional tests are being developed
(316,318). Postmarketing surveillance for neuraminidase
inhibitor-resistant influenza viruses is being conducted
Indications for Use of Antivirals When Susceptibility Exists
When administered within 2 days of illness onset to otherwise healthy adults, zanamivir and oseltamivir can reduce
the duration of uncomplicated influenza A and B illness by approximately 1 day compared with placebo
(91,320--334). More clinical data are available concerning the efficacy of zanamivir and oseltamivir for treatment of influenza A virus
infection than for treatment of influenza B virus infection
(324,335--344). However, in vitro data and studies of
treatment among mice and ferrets (345--352), in addition to clinical studies, have documented that zanamivir and oseltamivir have activity
against influenza B viruses
Data are limited regarding the effectiveness of the antiviral agents in preventing serious influenza-related
complications (e.g., bacterial or viral pneumonia or exacerbation of chronic diseases). Evidence for the effectiveness of these antiviral drugs
is principally based on studies of patients with uncomplicated influenza
(355). Data are limited concerning the effectiveness
of zanamivir and oseltamivir for treatment of influenza among persons at high risk for serious complications of
influenza (31,321,322,324,325,330--338). Among influenza virus infected participants in 10 clinical trials, the risk for
pneumonia among those participants receiving oseltamivir was approximately 50% lower than among those persons receiving a
placebo (339). A similar significant reduction was also found for hospital admissions; a 50% reduction was observed in the
small subset of high-risk participants, although this reduction was not statistically significant. Fewer studies of the efficacy
of influenza antivirals have been conducted among pediatric populations
(295,322,328,329). One study of oseltamivir treatment documented a decreased incidence of otitis media among children
(323). Inadequate data exist regarding the
safety and efficacy of any of the influenza antiviral drugs for use among children aged <1 year
Initiation of antiviral treatment within 2 days of illness onset is recommended. The recommended duration of
treatment with either zanamivir or oseltamivir is 5 days.
Chemoprophylactic drugs are not a substitute for vaccination, although they are critical adjuncts in preventing
and controlling influenza. In community studies of healthy adults, both oseltamivir and zanamivir are similarly effective
in preventing febrile, laboratory-confirmed influenza illness (efficacy: zanamivir, 84%; oseltamivir, 82%)
(324,340,356). Both antiviral agents also have been reported to prevent influenza illness among persons administered chemoprophylaxis after
a household member had influenza diagnosed
(341,353,356). Experience with chemoprophylactic use of these agents
institutional settings or among patients with chronic medical conditions is limited in comparison with the
adamantanes (310,337,338,342--344). One 6-week study of oseltamivir chemoprophylaxis among nursing home residents reported a
92% reduction in influenza illness (310,357). Use of zanamivir has not been reported to impair the immunologic response
to influenza vaccine (317,358). Data are not available regarding the efficacy of any of the four antiviral agents in
preventing influenza among severely immunocompromised persons.
When determining the timing and duration for administering influenza antiviral medications for chemoprophylaxis,
factors related to cost, compliance, and potential side effects should be considered. To be maximally effective as
chemoprophylaxis, the drug must be taken each day for the duration of influenza activity in the community.
Persons at High Risk Who Are Vaccinated After Influenza Activity Has Begun.
Persons at high risk for complications of influenza still can be vaccinated after an outbreak of influenza has begun in a community. However, development
of antibodies in adults after vaccination takes approximately 2 weeks
(265,266). When influenza vaccine is administered
while influenza viruses are circulating, chemoprophylaxis should be considered for persons at high risk during the time
from vaccination until immunity has developed. Children aged <9 years who receive influenza vaccine for the first time can
require 6 weeks of chemoprophylaxis (i.e., chemoprophylaxis for 4 weeks after the first dose of vaccine and an additional 2 weeks
of chemoprophylaxis after the second dose).
Persons Who Provide Care to Those at High Risk. To reduce the spread of virus to persons at high risk
during community or institutional outbreaks, chemoprophylaxis during peak influenza activity can be considered for
unvaccinated persons who have frequent contact with persons at high risk. Persons with frequent contact include employees of
hospitals, clinics, and chronic-care facilities; household members; visiting nurses; and volunteer workers. If an outbreak is caused by
a strain of influenza that might not be covered by the vaccine, chemoprophylaxis should be considered for all such
persons, regardless of their vaccination status.
Persons Who Have Immune Deficiencies. Chemoprophylaxis can be considered for persons at high risk who are
expected to have an inadequate antibody response to influenza vaccine. This category includes persons infected with HIV, chiefly
those with advanced HIV disease. No published data are available concerning possible efficacy of chemoprophylaxis among
persons with HIV infection or interactions with other drugs used to manage HIV infection. Such patients should be
monitored closely if chemoprophylaxis is administered.
Other Persons. Chemoprophylaxis throughout the influenza season or during peak influenza activity might be
appropriate for persons at high risk who should not be vaccinated. Chemoprophylaxis also can be offered to persons who wish to
avoid influenza illness. Health-care providers and patients should make this decision on an individual basis.
Control of Influenza Outbreaks in Institutions
Using antiviral drugs for treatment and chemoprophylaxis of influenza is a key component of influenza outbreak control
in institutions. In addition to antiviral medications, other outbreak-control measures include instituting droplet precautions
and establishing cohorts of patients with confirmed or suspected influenza, reoffering influenza vaccinations to unvaccinated
staff and patients, restricting staff movement between wards or buildings, and restricting contact between ill staff or visitors
and patients (359--361) (see Additional Information Regarding Influenza Virus Infection Control Among Specific Populations).
The majority of published reports concerning use of antiviral agents to control influenza outbreaks in institutions are
based on studies of influenza A outbreaks among nursing home populations that received amantadine or rimantadine
(335,362--366). Less information is available concerning use of neuraminidase inhibitors in influenza A or B institutional
outbreaks (337,338,344,357,367). When confirmed or suspected outbreaks of influenza occur in institutions that house persons at
high risk, chemoprophylaxis should be started as early as possible to reduce the spread of the virus. In these situations,
having preapproved orders from physicians or plans to obtain orders for antiviral medications on short notice can
substantially expedite administration of antiviral medications.
When outbreaks occur in institutions, chemoprophylaxis should be administered to all residents, regardless of whether
they received influenza vaccinations during the previous fall, and should continue for a minimum of 2 weeks. If
surveillance indicates that new cases continue to occur, chemoprophylaxis should be continued until approximately 1 week after the
end of the outbreak. The dosage for each resident should be determined individually. Chemoprophylaxis also can be offered
to unvaccinated staff members who provide care to persons at high risk. Chemoprophylaxis should be considered for
all employees, regardless of their vaccination status, if the outbreak is suspected to be caused by a strain of influenza virus that
is not well-matched to the vaccine.
In addition to nursing homes, chemoprophylaxis also can be considered for controlling influenza outbreaks in other
closed or semiclosed settings (e.g., dormitories or other settings in which persons live in close proximity).
To limit the potential transmission of drug-resistant virus during outbreaks in institutions, whether in chronic or
acute-care settings or other closed settings, measures should be taken to reduce contact as much as possible between persons
taking antiviral drugs for treatment and other persons, including those taking chemoprophylaxis (see Antiviral
Drug-Resistant Strains of Influenza Virus).
Dosage recommendations vary by age group and medical conditions (Table 6).
Zanamivir. Zanamivir is approved for treatment of influenza among children aged
>7 years. The recommended dosage of zanamivir for treatment of influenza is two inhalations (one 5-mg blister per inhalation for a total dose of 10 mg) twice
daily (approximately 12 hours apart); the chemoprophylaxis dosage of zanamivir for children aged
>5 years is 10 mg (two inhalations) once a day
Oseltamivir. Oseltamivir is approved for treatment and chemoprophylaxis among persons aged
>1 year. Recommended treatment and chemoprophylaxis dosages of oseltamivir for children vary by the weight of the child. The treatment
dosage recommendation of oseltamivir for children who weigh
<15 kg is 30 mg twice a day; for children weighing >15--23 kg,
45 mg twice a day; for those weighing >23--40 kg, 60 mg twice a day; and for children weighing >40 kg, 75 mg twice a
day (310). The chemoprophylaxis recommended dosage of oseltamivir for children weighing
<15 kg is 30 mg once a day; for those weighing >15--23 kg, 45 mg once a day; for those weighing >23--40 kg, 60 mg once a day; and for those weighing
>40 kg, 75 mg once a day.
Persons Aged >65 Years
Zanamivir and Oseltamivir. No reduction in dosage is recommended on the basis of age alone.
Persons with Impaired Renal Function
Zanamivir. Limited data are available regarding the safety and efficacy of zanamivir for patients with impaired
renal function. Among patients with renal failure who were administered a single intravenous dose of zanamivir, decreases in
renal clearance, increases in half-life, and increased systemic exposure to zanamivir were observed
(317,368). However, a limited number of healthy volunteers who received high doses of zanamivir intravenously tolerated systemic levels of zanamivir
that were substantially higher than those resulting from administration of zanamivir by oral inhalation at the recommended
dose (369,370). On the basis of these considerations, the manufacturer recommends no dose adjustment for inhaled zanamivir
for a 5-day course of treatment for patients with either mild-to-moderate or severe impairment in renal function
Oseltamivir. Serum concentrations of oseltamivir carboxylate, the active metabolite of oseltamivir, increase with
declining renal function (310,371). For patients with creatinine clearance of 10--30 mL/min
(310), a reduction of the treatment dosage of oseltamivir to 75 mg once daily and in the chemoprophylaxis dosage to 75 mg every other day is recommended.
No treatment or chemoprophylaxis dosing recommendations are available for patients undergoing routine renal
Persons with Liver Disease
Zanamivir and Oseltamivir. Neither of these medications has been studied among persons with hepatic dysfunction.
Persons with Seizure Disorders
Zanamivir and Oseltamivir. Seizure events have been reported during postmarketing use of zanamivir and
oseltamivir, although no epidemiologic studies have reported any increased risk for seizures with either zanamivir or oseltamivir use.
Oseltamivir is administered orally in capsule or oral suspension form. Zanamivir is available as a dry powder that is
self-administered via oral inhalation by using a plastic device included in the package with the medication. Patients will benefit
from instruction and demonstration of correct use of this device.
In studies of healthy volunteers, approximately 7%--21% of the orally inhaled zanamivir dose reached the lungs, and
70%--87% was deposited in the oropharynx
(317,372). Approximately 4%--17% of the total amount of orally inhaled zanamivir
is systemically absorbed. Systemically absorbed zanamivir has a half-life of 2.5--5.1 hours and is excreted unchanged in the
urine. Unabsorbed drug is excreted in the feces
Approximately 80% of orally administered oseltamivir is absorbed systemically
(371). Absorbed oseltamivir is metabolized to oseltamivir carboxylate, the active neuraminidase inhibitor, primarily by hepatic esterases. Oseltamivir carboxylate has
a half-life of 6--10 hours and is excreted in the urine by glomerular filtration and tubular secretion via the anionic
pathway (310,373). Unmetabolized oseltamivir also is excreted in the urine by glomerular filtration and tubular secretion
Side Effects and Adverse Reactions
When considering use of influenza antiviral medications (i.e., choice of antiviral drug, dosage, and duration of
therapy), clinicians must consider the patient's age, weight, and renal function (Table 6); presence of other medical
conditions; indications for use (i.e., chemoprophylaxis or treatment); and the potential for interaction with other medications.
In a study of zanamivir treatment of ILI among persons with asthma or chronic obstructive pulmonary disease where
study medication was administered after use of a B2-agonist, 13% of patients receiving zanamivir and 14% of patients who
received placebo (inhaled powdered lactose vehicle) experienced a >20% decline in forced expiratory volume in 1 second (FEV1)
after treatment (317,330). However, in a phase I study of persons with mild or moderate asthma who did not have ILI, one of
13 patients experienced bronchospasm after administration of zanamivir
(317). In addition, during postmarketing
surveillance, cases of respiratory function deterioration after inhalation of zanamivir have been reported. Certain patients had
underlying airway disease (e.g., asthma or chronic obstructive pulmonary disease). Because of the risk for serious adverse events
and because the efficacy has not been demonstrated among this population, zanamivir is not recommended for treatment
for patients with underlying airway disease
(317). If physicians decide to prescribe zanamivir to patients with underlying
chronic respiratory disease after carefully considering potential risks and benefits, the drug should be used with caution
under conditions of appropriate monitoring and supportive care, including the availability of short-acting bronchodilators
(355). Patients with asthma or chronic obstructive pulmonary disease who use zanamivir are advised to 1) have a fast-acting
inhaled bronchodilator available when inhaling zanamivir and 2) stop using zanamivir and contact their physician if they
experience difficulty breathing (317). No definitive evidence is available regarding the safety or efficacy of zanamivir for persons
with underlying respiratory or cardiac disease or for persons with complications of acute influenza
(355). Allergic reactions, including oropharyngeal or facial edema, also have been reported during postmarketing surveillance
In clinical treatment studies of persons with uncomplicated influenza, the frequencies of adverse events were similar for
persons receiving inhaled zanamivir and for those receiving placebo (i.e., inhaled lactose vehicle alone)
(320--325,337). The most common adverse events reported by both groups were diarrhea; nausea; sinusitis; nasal signs and symptoms; bronchitis;
cough; headache; dizziness; and ear, nose, and throat infections. Each of these symptoms was reported by <5% of persons in the
clinical treatment studies combined (317).
Nausea and vomiting were reported more frequently among adults receiving oseltamivir for treatment (nausea
without vomiting, approximately 10%; vomiting, approximately 9%) than among persons receiving placebo (nausea
without vomiting, approximately 6%; vomiting, approximately 3%)
(310,326,327,374). Among children treated with
oseltamivir, 14% had vomiting, compared with 8.5% of placebo recipients. Overall, 1% discontinued the drug secondary to this
side effect (329), whereas a limited number of adults who were enrolled in clinical treatment trials of oseltamivir
discontinued treatment because of these symptoms
(310). Similar types and rates of adverse events were reported in studies of
oseltamivir chemoprophylaxis (310). Nausea and vomiting might be less severe if oseltamivir is taken with food
Use During Pregnancy
No clinical studies have been conducted regarding the safety or efficacy of zanamivir or oseltamivir for pregnant
women. Because of the unknown effects of influenza antiviral drugs on pregnant women and their fetuses, these two drugs should
be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus. Oseltamivir
and zanamivir are both "Pregnancy Category C" medications (see manufacturers' package inserts)
Clinical data are limited regarding drug interactions with zanamivir. However, no known drug interactions have
been reported, and no clinically critical drug interactions have been predicted on the basis of in vitro data and data from
studies using rats (310,373).
Limited clinical data are available regarding drug interactions with oseltamivir. Because oseltamivir and
oseltamivir carboxylate are excreted in the urine by glomerular filtration and tubular secretion via the anionic pathway, a potential
exists for interaction with other agents excreted by this pathway. For example, coadministration of oseltamivir and
probenecid resulted in reduced clearance of oseltamivir carboxylate by approximately 50% and a corresponding approximate
twofold increase in the plasma levels of oseltamivir carboxylate
No published data are available concerning the safety or efficacy of using combinations of any of these influenza
antiviral drugs. For more detailed information concerning potential drug interactions for any of these influenza antiviral
drugs, package inserts should be consulted.
Information Regarding the Vaccines for Children Program
The Vaccines for Children (VFC) program supplies vaccine to all states, territories, and the District of Columbia for use
by participating providers. These vaccines are to be administered to eligible children
without vaccine cost to the patient, as well
as the provider. All routine childhood vaccines recommended by ACIP are available through this program. The program
saves parents and providers out-of-pocket expenses for vaccine purchases and provides cost-savings to states through the
CDC vaccine contracts. The program results in lower vaccine prices and assures that all states pay the same contract prices.
Detailed information regarding the VFC program is available at
Sources of Information Regarding Influenza and Its Surveillance
Information regarding influenza surveillance, prevention, detection, and control is available at
http://www.cdc.gov/flu/weekly/fluactivity.htm. Surveillance information is available through the CDC Voice Information System (influenza
update) at 888-232-3228 or CDC Fax Information Service at 888-232-3299. During October--May, surveillance information
is updated weekly. In addition, periodic updates regarding influenza are published in the
MMWR Weekly Report (http://www.cdc.gov/mmwr). Additional information regarding influenza vaccine can be obtained by calling 800-CDC-INFO
(800-232-4636). State and local health departments should be consulted concerning availability of influenza vaccine, access
to vaccination programs, information related to state or local influenza activity, reporting of influenza outbreaks and
influenza-related pediatric deaths, and advice concerning outbreak control.
Reporting of Adverse Events Following Vaccination
Clinically significant adverse events that follow vaccination should be reported through VAERS at
or by calling the 24-hour national toll-free hotline at
Additional Information Regarding Influenza Virus Infection Control
Among Specific Populations
Each year, ACIP provides general, annually updated information regarding control and prevention of influenza.
Other reports related to controlling and preventing influenza among specific populations (e.g., immunocompromised
persons, health-care workers, hospital patients, pregnant women, children, and travelers) also are available in the
American Academy of Pediatrics. 2006 red book: report of the Committee on Infectious Diseases. 27th ed. Elk
Grove Village, IL: American Academy of Pediatrics; 2006.
American College of Obstetricians and Gynecologists. Influenza vaccination and treatment during pregnancy. ACOG committee opinion no. 305. Obstet Gynecol 2004;104:1125--6.
Bodnar UR, Maloney SA, Fielding KL, et al. Preliminary guidelines for the prevention and control of
influenza-like illness among passengers and crew members on cruise ships. Atlanta, GA: US Department of Health and
Human Services, CDC, National Center for Infectious Diseases; 1999.
Bradley SF. The Long-Term--Care Committee of the Society for Health-care Epidemiology of America. Prevention
of influenza in long-term care facilities. Infect Control Hosp Epidemiol 1999;20:629--37.
CDC. Influenza vaccination of health-care personnel: recommendations of the Healthcare Infection Control
Practices Advisory Committee (HICPAC) and the Advisory Committee on Immunization Practices (ACIP).
MMWR 2006;55(No. RR-2).
CDC. General recommendations on immunization: recommendations of the Advisory Committee on
Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). MMWR 2002;51(No.
CDC. Detection and control of influenza outbreaks in acute care facilities. Atlanta, GA: US Department of Health
and Human Services, CDC, National Center for Infections Diseases; 2001.
Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in
hospitals. Infect Control Hosp Epidemiol 1996;17:53--80.
Sneller V-P, Izurieta H, Bridges C, et al. Prevention and control of vaccine-preventable diseases in long-term
care facilities. Journal of the American Medical Directors Association 2000;1(Suppl):S2--37.
US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). USPHS/IDSA Prevention
of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic
infections in persons infected with human immunodeficiency virus. Final November 28, 2001:1--65. Available at
Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States.
Monto AS, Kioumehr F. The Tecumseh Study of Respiratory Illness. IX. Occurence of influenza in the community, 1966--1971. Am J
Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974--76. N Engl J Med 1978;298:587--92.
Glezen WP, Greenberg SB, Atmar RL, et al. Impact of respiratory virus infections on persons with chronic underlying conditions.
Barker WH. Excess pneumonia and influenza associated hospitalization during influenza epidemics in the United States, 1970--78. Am J
Public Health 1986;76:761--5.
Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112:798--811.
Glezen WP. Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev 1982;4:25--44.
Office of Technology Assessment. Cost effectiveness of influenza vaccination. In: U.S. Congress. Washington, DC: Office of
Technology Assessment; 1981.
Wilde JA, McMillan JA, Serwint J, et al. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA
Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med
Campbell DS, Rumley MH. Cost-effectiveness of the influenza vaccine in a healthy, working-age population. J Occup Environ Med
Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a
randomized controlled trial. JAMA 2000;284:1655--63.
Patriarca PA, Weber JA, Parker RA, et al. Risk factors for outbreaks of influenza in nursing homes. A case-control study. Am J
Gross PA, Hermogenes AW, Sacks HS, et al. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature.
Ann Intern Med 1995;123:518--27.
Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health
maintenance organization. Ann Intern Med 1994;121:947--52.
Clements DA, Langdon L, Bland C, et al. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day
care. Arch Pediatr Adolesc Med 1995;149:1113--7.
Heikkinen T, Ruuskanen O, Waris M, et al. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis
Nordin J, Mullooly J, Poblete S, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in persons 65 years or older
in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001;184:665--70.
Ndiaye SM, Hopkins DP, Shefer AM, et al. Interventions to improve influenza, pneumococcal polysaccharide, and hepatitis B vaccination
coverage among high-risk adults: a systematic review. Am J Prev Med 2005;28(5 Suppl):248--79.
Clements ML, Betts RF, Tierney EL, et al. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza
A wild-type virus. J Clin Microbiol 1986;24:157--60.
Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983;37:529--49.
Cox NJ, Subbarao K. Influenza. Lancet 1999;354(9186):1277--82.
Frank AL, Taber LH, Wells CR, et al. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis 1981;144:433--41.
Klimov AI, Rocha E, Hayden FG, et al. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients:
detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995;172:1352--5.
Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in
symptomatic immunocompromised adults. Clin Infect Dis 1998;26:1418--24.
Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral
therapy in an immunocompromised patient. Clin Infect Dis 2002;34:E23--5.
Nicholson KG. Clinical features of influenza. Semin Respir Infect 1992;7:26--37.
Ryan-Poirier K. Influenza virus infection in children. Adv Pediatr Infect Dis 1995;10:125--56.
Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis 2003;36:299--305.
Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J
Infect Dis 2002;185:147--52.
Douglas R Jr. Influenza in man. In: Kilbourne ED, ed. Influenza viruses and influenza. New York, NY: Academic Press, Inc.; 1975:395--418.
Dagan R, Hall CB. Influenza A virus infection imitating bacterial sepsis in early infancy. Pediatr Infect Dis 1984;3:218--21.
Chiu SS, Tse CY, Lau YL, et al. Influenza A infection is an important cause of febrile seizures. Pediatrics 2001;108:E63.
McCullers JA, Facchini S, Chesney PJ, et al. Influenza B virus encephalitis. Clin Infect Dis 1999;28:898--900.
Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalopathy associated with an influenza epidemic in Japan. Clin Infect
Boivin G, Hardy I, Tellier G, et al. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect
Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000;160:3243--7.
Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev 1988;10:212--41.
Govaert TM, Dinant GJ, Aretz K, et al. The predictive value of influenza symptomatology in elderly people. Fam Pract 1998;15:16--22.
Walsh EE, Cox C, Falsey AR. Clinical features of influenza A virus infection in older hospitalized persons. J Am Geriatr Soc 2002;50:1498--503.
Neuzil KM, O'Connor TZ, Gorse GJ, et al. Recognizing influenza in older patients with chronic obstructive pulmonary disease who have
received influenza vaccine. Clin Infect Dis 2003;36:169--74.
Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333--40.
Simonsen L, Schonberger LB, Stroup DF, et al. Impact of influenza on mortality in the USA. In: Proceedings of the 3rd International
Conference on Options for the Control of Influenza, Cairns, Australia. Brown LE, Webster RG, eds. Amsterdam: Elsevier Science; 1996:26--32.
Lui KJ, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public
Noble G. Epidemiological and clinical aspects of influenza. In: Beare AS, ed. Basic and applied influenza research. Boca Raton, FL: CRC
Eickhoff TC, Sherman IL, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA 1961;176:776--82.
Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 1982;142:85--9.
Simonsen L, Clarke MJ, Schonberger LB, et al. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect
Keren R, Zaoutis TE, Bridges CB, et al. Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized
with influenza infection. JAMA 2005;294:2188--94.
Grijalva CG, Craig AS, Dupont WD, et al. Estimating influenza hospitalizations among children. EID 2006;12:103--9.
Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during
influenza epidemics in Houston, 1978--1981. Am Rev Respir Dis 1987;136:550--5.
Neuzil KM, Wright PF, Mitchel EF Jr, et al. The burden of influenza illness in children with asthma and other chronic medical conditions.
J Pediatr 2000;137:856--64.
Izurieta HS, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young
children. N Engl J Med 2000;342:232--9.
Neuzil KM, Mellen BG, Wright PF, et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children.
N Engl J Med 2000;342:225--31.
Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333--40.
Simonsen L, Fukuda K, Schonberger LB, et al. The impact of influenza epidemics on hospitalizations. J Infect Dis 2000;181:831--7.
National Center for Health Statistics. Health, United States, 1998. Hyattsville, MD: US Department of Health and Human Services, CDC; 1998.
Simonsen L, Clarke MJ, Williamson GD, et al. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public
Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med
Kilbourne E. Influenza. New York, NY: Plenum Medical Book Company; 1987.
La Montagne JR, Noble GR, Quinnan GV, et al. Summary of clinical trials of inactivated influenza vaccine---1978. Rev Infect Dis
Oxford JS, Schild GC, Potter CW, et al. The specificity of the anti-haemagglutinin antibody response induced in man by inactivated
influenza vaccines and by natural infection. J Hyg (Lond) 1979;82:51--61.
Neuzil KM, Dupont WD, Wright PF, et al. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990:
the pediatric experience. Pediatr Infect Dis J 2001;20:733--40.
Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35:69--75.
Hirota Y, Kaji M, Ide S, et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 1997;15:962--7.
Gonzalez M, Pirez MC, Ward E, et al. Safety and immunogenicity of a paediatric presentation of an influenza vaccine. Arch Dis
Wright PF, Cherry JD, Foy HM, et al. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children---a
multicentered evaluation of dosage and safety. Rev Infect Dis 1983;5:758--64.
Daubeney P, Taylor CJ, McGaw J, et al. Immunogenicity and tolerability of a trivalent influenza subunit vaccine (Influvac) in high-risk
children aged 6 months to 4 years. Br J Clin Pract 1997;51:87--90.
Wright PF, Thompson J, Vaughn WK, et al. Trials of influenza
A/New Jersey/76 virus vaccine in normal children: an overview of
age-related antigenicity and reactogenicity. J Infect Dis 1977;136(Suppl):S731--41.
Negri E, Colombo C, Giordano L, et al. Influenza vaccine in healthy children: a meta-analysis. Vaccine 2005;23:2851--61.
Jefferson T, Smith S, Demicheli V, et al. Assessment of the efficicacy and effectiveness of influenza vaccines in healthy children: a
systematic review. Lancet 2005;365:773--80.
Groothuis JR, Lehr MV, Levin MJ. Safety and immunogenicity of a purified haemagglutinin antigen in very young high-risk children.
Park CL, Frank AL, Sullivan M, et al. Influenza vaccination of children during acute asthma exacerbation and concurrent prednisone
therapy. Pediatrics 1996;98(2 Pt 1):196--200.
Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children:
a randomized controlled trial. JAMA 2003;290:1608--16.
Clover RD, Crawford S, Glezen WP, et al. Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated
and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 1991;163:300--4.
Sugaya N, Nerome K, Ishida M, et al. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type
B. JAMA 1994;272:1122--6.
Ritzwoller DP, Bridges CB, Sheetterly S, et al. Effectiveness of the 2003--04 influenza vaccine among children 6 months to 8 years for 1 versus
2 doses. Pediatrics 2005;116:153--9.
Shuler C, Iwamoto M, Neeman R, et al. Influenza vaccine effectiveness against laboratory-confirmed influenza among children age 6 to
59 Months---Georgia, 2003--2004 [Poster #1008]. Presented at the 43rd Annual Meeting of the Infectious Diseases Society of America,
San Francisco, CA; 2005.
Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of one versus two doses of trivalent inactivated influenza vaccine
in vaccine-naïve 5-8-year-old children. J Infect Dis. In press 2006.
Englund JA, Walter EB, Fairchok MP, et al. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children.
Walter EB, Neuzil KM, Zhu Y, et al. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary
for priming? Pediatrics. In press 2006.
Palache AM. Influenza vaccines. A reappraisal of their use. Drugs 1997;54:841--56.
Demicheli V, Jefferson T, Rivetti D, et al. Prevention and early treatment of influenza in healthy adults. Vaccine 2000;18:957--1030.
Smith JW, Pollard R. Vaccination against influenza: a five-year study in the Post Office. J Hyg (Lond) 1979;83:157--70.
Hak E, Nordin J, Wei F, et al. Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of
3 large managed-care organizations. Clin Infect Dis 2002;35:370--7.
Jefferson T, Rivetti D, Rudin M, et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review.
Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect
Dorrell L, Hassan I, Marshall S, et al. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection,
diabetes, obstructive airways disease, elderly adults and healthy volunteers. Int J STD AIDS 1997;8:776--9.
McElhaney JE, Beattie BL, Devine R, et al. Age-related decline in interleukin 2 production in response to influenza vaccine. J Am Geriatr
Govaert TM, Thijs CT, Masurel N, et al. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind
placebo-controlled trial. JAMA 1994;272:1661--5.
Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern
Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes. Reduction in illness and complications during
an influenza A (H3N2) epidemic. JAMA 1985;253:1136--9.
Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Options for
the Control of Influenza. New York, NY: Alan R. Liss, Inc.; 1986.
Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J
Riddiough MA, Sisk JE, Bell JC. Influenza vaccination. JAMA 1983;249:3189--95.
King JC Jr, Lagos R, Bernstein DI, et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza
vaccine administered intranasally as drops or spray to healthy children. J Infect Dis 1998;177:1394--7.
Belshe RB, Gruber WC, Mendelman PM, et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent,
intranasal influenza virus vaccine. J Infect Dis 2000;181:1133--7.
Boyce TG, Gruber WC, Coleman-Dockery SD, et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine
in children. Vaccine 1999;18:82--8.
Zangwill KM, Droge J, Mendelman P, et al. Prospective, randomized, placebo-controlled evaluation of the safety and immunogenicity of three
lots of intranasal trivalent influenza vaccine among young children. Pediatr Infect Dis J 2001;20:740--6.
Bernstein DI, Yan L, Treanor J, et al. Effect of yearly vaccinations with live, attenuated, cold-adapted, trivalent, intranasal influenza vaccines
on antibody responses in children. Pediatr Infect Dis J 2003;22:28--34.
Nolan T, Lee MS, Cordova JM, et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two
manufacturing facilities. Vaccine 2003;21:1224--31.
Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in
children. N Engl J Med 1998;338:1405--12.
Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza
virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000;136:168--75.
Halloran ME, Longini IM Jr, Gaglani MJ, et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against
influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 2003;158:305--11.
Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults:
a randomized controlled trial. JAMA 1999;282:137--44.
Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in
prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine
Mixeu MA, Vespa GN, Forleo-Neto E, et al. Impact of influenza vaccination on civilian aircrew illness and absenteeism. Aviat Space Environ
Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on
the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003;21:2207--17.
Nichol KL, Mendelman P. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative
and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses. Virus Res 2004;103:3--8.
Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001;161:749--59.
Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000;106:973--6.
White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 1999;103:e73.
Dayan GH, Nguyen VH, Debbag R, et al. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine
Luce BR, Zangwill KM, Palmer CS, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in
healthy children. Pediatrics 2001;108:E24.
Prosser LA, Bridges CB, Uyeki TM, et al. Values for preventing influenza-related morbidity and vaccine adverse events in children. Health
and Quality of Life Outcomes 2005;3. Available at
US Department of Health and Human Services. Healthy people 2010 (conference ed., in 2 vols). Washington, DC: US Department of Health
and Human Services; 2000.
US Department of Health and Human Services. Healthy people 2000: national health promotion and disease prevention objectives---full
report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service; 1991.
Herbert PL, Frick KD, Kane RL, McBean AM. The causes of racial and ethnic differences in influenza vaccination rates among elderly
Medicare beneficiaries. Health Serv Res 2005;40:517--37.
Winston CA, Wortley PM, Lees KA. Factors associated with vaccination of Medicare beneficiaries in five U.S. communities: Results from
the Racial and Ethnic Adult Disparities in Immunization Initiative survey, 2003. J Am Geriatr Soc 2006;54:303--10.
Buikema AR, Singleton JA, Sneller VP, Strikas RA. Influenza vaccination in nursing homes, United States, 1995 and 1997 [Abstract
P2-49]. Presented at the Options for the Control of Influenza IV Conference, Crete, Greece; September 23--28, 2000.
Zadeh MM, Buxton Bridges C, Thompson WW, et al. Influenza outbreak detection and control measures in nursing homes in the United States.
J Am Geriatr Soc 2000;48:1310--5.
Kramarz P, DeStefano F, Gargiullo PM, et al. Influenza vaccination in children with asthma in health maintenance organizations. Vaccine
Safety Datalink Team. Vaccine 2000;18:2288--94.
Chung EK, Casey R, Pinto-Martin JA, et al. Routine and influenza vaccination rates in children with asthma. Ann Allergy Asthma
Gaglani M, Riggs M, Kamenicky C, et al. A computerized reminder strategy is effective for annual influenza immunization of children
with asthma or reactive airway disease. Pediatr Infect Dis J 2001;20:1155--60.
Marshall BC, Henshaw C, Evans DA, et al. Influenza vaccination coverage level at a cystic fibrosis center. Pediatrics 2002;109:E80--0.
Nowalk MP, Zimmerman RK, Lin CJ, et al. Parental perspectives on influenza immunization of children aged 6 to 23 months. Am J Prev
Potter J, Stott DJ, Roberts MA, et al. Influenza vaccination of health care workers in long-term-care hospitals reduces the mortality of
elderly patients. J Infect Dis 1997;175:1--6.
Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care personnel on mortality of elderly people in
long-term care: a randomised controlled trial. Lancet 2000;355(9198):93--7.
National Foundation for Infectious Diseases. Call to action: influenza immunization among health-care personnel, 2003. Bethesda, MD:
National Foundation for Infectious Diseases; 2003. Available at
Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine 2005;23:2251--5.
Lu P, Singleton J. Influenza vaccination of pregnant women: Behavioral Risk Factor Surveillance System (BRFSS), 1997--2001. Presented at
the Annual Behavioral Risk Factor Surveillance System Conference; St. Louis, Missouri, 2003.
Yeager DP, Toy EC, Baker B III. Influenza vaccination in pregnancy. Am J Perinatol 1999;16:283--6.
Gonik B, Jones T, Contreras D, et al. The obstetrician-gynecologist's role in vaccine-preventable diseases and immunization. Obstet
Zimmerman RK, Raymund M, Janosky JE, et al. Sensitivity and specificity of patient self-report of influenza and pneumococcal
polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine 2003;21:1486--91.
Poehling KA, Edwards KM, Weinberg GA, et al. The Under-Recognized Burden of Influenza Illness in Young Children. N Engl J Med. In
Iwane MK, Edwards KM, Szilagyi PG, et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus,
influenza virus, and parainfluenza viruses among young children. Pediatrics 2004;113:1758--64.
Schrag SJ, Shay DK, Gershman K, et al. Multistate surveillance for laboratory-confirmed influenza-associated hospitalizations in children,
2003--2004. Pediatr Infect Dis J 2006;25:395--400.
Mullooly JP, Barker WH. Impact of type A influenza on children: a retrospective study. Am J Public Health 1982;72:1008--16.
Glezen WP, Decker M, Joseph SW, et al. Acute respiratory disease associated with influenza epidemics in Houston, 1981--1983. J Infect
Louie JK, Schechter R, Honarmand S, et al. Severe pediatric influenza in California, 2003--2005: Implications for
immunization recommendations. Pediatrics 2006;117:610--8.
Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps
and respiratory syncytial viruses and Mycoplasma pneumoniae. Am J Epidemiol 1975;101:532--51.
Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child
Glezen WP. Morbidity associated with the major respiratory viruses. Pediatr Ann 1990;19:535--6, 538, 540, passim.
Harris JW. Influenza occurring pregnant women: a statistical study of thirteen hundred and fifty cases. JAMA 1919;72:978--80.
Widelock D, Csizmas L, Klein S. Influenza, pregnancy, and fetal outcome. Public Health Rep 1963;78:1--11.
Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 1959;78:1172--5.
Shahab SZ, Glezen WP. Influenza virus. In: Gonik B, ed. Viral diseases in pregnancy. New York, NY: Springer-Verlag; 1994:215--23.
Schoenbaum SC, Weinstein L. Respiratory infection in pregnancy. Clin Obstet Gynecol 1979;22:293--300.
Kirshon B, Faro S, Zurawin RK, et al. Favorable outcome after treatment with amantadine and ribavirin in a pregnancy complicated by
influenza pneumonia. A case report. J Reprod Med 1988;33:399--401.
Kort BA, Cefalo RC, Baker VV. Fatal influenza A pneumonia in pregnancy. Am J Perinatol 1986;3:179--82.
Irving WL, James DK, Stephenson T, et al. Influenza virus infection in the second and third trimesters of pregnancy: a clinical
and seroepidemiological study. BJOG 2000;107:1282--9.
Neuzil KM, Reed GW, Mitchel EF, et al. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J
Heinonen OP, Shapiro S, Monson RR, et al. Immunization during pregnancy against poliomyelitis and influenza in relation to
childhood malignancy. Int J Epidemiol 1973;2:229--35.
Munoz FM, Greisinger AJ, Wehmanen OA, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol. 2005;192:1098--106.
O'Mara D, Fukuda K, Singleton JA. Influenza vaccine: ensuring timely and adequate supply. Infect Med 2003;20:548--54.
Fedson DS. Adult immunization. Summary of the National Vaccine Advisory Committee Report. JAMA 1994;272:1133--7.
Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live
attenuated influenza vaccine (CAIV-T) in children. Vaccine 2005;23:1540--8.
King JC Jr, Cummings GE, Stoddard J, et al. A pilot study of the effectiveness of a school-based vaccination program. Pediatrics
Talbot TR, Bradley SF, Cosgrove SE, et al. SHEA Position Paper: Influenza vaccination of healthcare workers and vaccine allocation for health
care workers during vaccine shortages. Infection Control and Hospital Epidemiology 2005;26:882--90.
Couch RB. Influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin Infect Dis 1999;28:548--51.
Tasker SA, O'Brien WA, Treanor JJ, et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial.
Neuzil KM, Reed GW, Mitchel EF Jr, et al. Influenza-associated morbidity and mortality in young and middle-aged women.
Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired
immunodeficiency syndrome. Arch Intern Med 2001;161:441--6.
Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990;98:33--7.
Radwan HM, Cheeseman SH, Lai KK, et al. Influenza in human immunodeficiency virus-infected patients during the 1997--1998
influenza season. Clin Infect Dis 2000;31:604--6.
Fine AD, Bridges CB, De Guzman AM, et al. Influenza A among patients with human immunodeficiency virus: an outbreak of infection at
a residential facility in New York City. Clin Infect Dis 2001;32:1784--91.
Chadwick EG, Chang G, Decker MD, et al. Serologic response to standard inactivated influenza vaccine in human immunodeficiency
virus-infected children. Pediatr Infect Dis J 1994;13:206--11.
Huang KL, Ruben FL, Rinaldo CR Jr, et al. Antibody responses after influenza and pneumococcal immunization in HIV-infected
homosexual men. JAMA 1987;257:2047--50.
Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp
Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year
study. Vaccine 2000;18:3040--9.
Miotti PG, Nelson KE, Dallabetta GA, et al. The influence of HIV infection on antibody responses to a two-dose regimen of influenza
vaccine. JAMA 1989;262:779--83.
Ho DD. HIV-1 viraemia and influenza. Lancet 1992;339(8808):1549.
O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood
of seropositive patients after influenza vaccination. Blood 1995;86:1082--9.
Glesby MJ, Hoover DR, Farzadegan H, et al. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a
randomized, double-blind, placebo-controlled study. J Infect Dis 1996;174:1332--6.
Fowke KR, D'Amico R, Chernoff DN, et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients.
Fuller JD, Craven DE, Steger KA, et al. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels
of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999;28:541--7.
Amendola A, Boschini A, Colzani D, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J
Med Virol 2001;65:644--8.
Sullivan PS, Hanson DL, Dworkin MS, et al. Effect of influenza vaccination on disease progression among HIV-infected persons.
Gunthard HF, Wong JK, Spina CA, et al. Effect of influenza vaccination on viral replication and immune response in persons infected with
human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis 2000;181:522--31.
Miller JM, Tam TW, Maloney S, et al. Cruise ships: high-risk passengers and the global spread of new influenza viruses. Clin Infect
Uyeki TM, Zane SB, Bodnar UR, et al. Large summertime influenza A outbreak among tourists in Alaska and the Yukon Territory. Clin Infect
Nichol KL, D'Heilly S, Ehlinger E. Colds and influenza-like illness in university students: impact on health, academic and work performance,
and health care use. Clin Infect Dis 2005;40:1263--70.
Gross PA, Weksler ME, Quinnan GV Jr, et al. Immunization of elderly people with two doses of influenza vaccine. J Clin
Feery BJ, Cheyne IM, Hampson AW, et al. Antibody response to one and two doses of influenza virus subunit vaccine. Med J Aust
Levine M, Beattie BL, McLean DM. Comparison of one- and two-dose regimens of influenza vaccine for elderly men. CMAJ 1987;137:722--6.
Cate TR, Couch RB, Parker D, et al. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus
vaccines---1978. Rev Infect Dis 1983;5:737--47.
Kunzel W, Glathe H, Engelmann H, et al. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in
subjects previously vaccinated or vaccinated for the first time. Vaccine 1996;14:1108--10.
Poland GA, Borrud A, Jacobson RM, et al. Determination of deltoid fat pad thickness. Implications for needle length in adult
immunization. JAMA 1997;277:1709--11.
Govaert TM, Dinant GJ, Aretz K, et al. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled
trial. BMJ 1993;307:988--90.
Margolis KL, Nichol KL, Poland GA, et al. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized,
placebo-controlled trial. JAMA 1990;264:1139--41.
Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults. A randomized,
placebo-controlled trial. Arch Intern Med 1996;156:1546--50.
American Lung Association Asthma Clinical Research Centers. The safety of inactivated influenza vaccine in adults and children with asthma.
N Engl J Med 2001;345:1529--36.
Piedra PA, Glezen WP, Mbawuike I, et al. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type
A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine 1993;11:718--24.
Scheifele DW, Bjornson G, Johnston J. Evaluation of adverse events after influenza vaccination in hospital personnel. CMAJ 1990;142:127--30.
Barry DW, Mayner RE, Hochstein HD, et al. Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am J
France EK, Jackson L, Vaccine Safety Datalink Team. Safety of the trivalent inactivated influenza vaccine among children: a
population-based study [Abstract 76]. Presented at the National Immunization Conference, Chicago, Illinois; 2003.
Groothuis JR, Levin MJ, Rabalais GP, et al. Immunization of high-risk infants younger than 18 months of age with split-product influenza
vaccine. Pediatrics 1991;87:823--8.
McMahon AW, Iskander J, Haber P, et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis
of reports from the vaccine adverse event reporting system, 1990--2003. Pediatrics 2005;115:453--60.
France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch
Pediatr Adolesc Med 2004;158:1031--6.
Bierman CW, Shapiro GG, Pierson WE, et al. Safety of influenza vaccination in allergic children. J Infect Dis 1977;136(Suppl):S652--5.
James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998;133:624--8.
Murphy KR, Strunk RC. Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins. J Pediatr 1985;106:931--3.
Zeiger RS. Current issues with influenza vaccination in egg allergy. J Allergy Clin Immunol 2002;110:834--40.
Aberer W. Vaccination despite thimerosal sensitivity. Contact Dermatitis 1991;24:6--10.
Kirkland LR. Ocular sensitivity to thimerosal: a problem with hepatitis B vaccine? South Med J 1990;83:497--9.
Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza
Immunization Program, United States, 1976--1977. Am J Epidemiol 1979;110:105--23.
Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine
influenza vaccine in 1976--1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991;133:940--51.
Ropper AH. The Guillain-Barre syndrome. N Engl J Med 1992;326:1130--6.
Hurwitz ES, Schonberger LB, Nelson DB, et al. Guillain-Barre syndrome and the 1978--1979 influenza vaccine. N Engl J Med
Kaplan JE, Katona P, Hurwitz ES, et al. Guillain-Barre syndrome in the United States, 1979--1980 and 1980--1981. Lack of an association
with influenza vaccination. JAMA 1982;248:698--700.
Chen R, Kent J, Rhodes P, et al. Investigations of a possible association between influenza vaccination and Guillain-Barre syndrome in the
United States, 1990--1991 [Abstract 040]. Post Marketing Surveillance 1992;6:5--6.
Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992--1993 and 1993--1994 influenza vaccines.
N Engl J Med 1998;339:1797--802.
Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barre syndrome following influenza vaccination. JAMA 2004;292:2478--81.
Horner FA. Neurologic disorders after Asian influenza. N Engl J Med 1958;258:983--5.
Jacobs BC, Rothbarth PH, van der Meche FG, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control
study. Neurology 1998;51:1110--5.
Guarino M, Casmiro M, D'Alessandro R.
Campylobacter jejuni infection and Guillain-Barre syndrome: a case-control study.
Emilia-Romagna Study Group on Clinical and Epidemiological problems in neurology. Neuroepidemiology 1998;17:296--302.
Sheikh KA, Nachamkin I, Ho TW, et al.
Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome: molecular mimicry and
host susceptibility. Neurology 1998;51:371--8.
Prevots DR, Sutter RW. Assessment of Guillain-Barre syndrome mortality and morbidity in the United States: implications for acute flaccid
paralysis surveillance. J Infect Dis 1997;175(Suppl 1):S151--5.
Barohn RJ, Saperstein DS. Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy. Semin Neurol 1998;18:49--61.
Stratton K, Gable A, McCormick MC, eds. Immunization safety review: thimerosal-containing vaccines and neurodevelopmental
disorders. Washington, DC: National Academy Press; 2001.
Pichichero ME, Cernichiari E, Lopreiato J, et al. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal:
a descriptive study. Lancet 2002;360(9347):1737--41.
CDC. Summary of the joint statement on thimerosal in vaccines. MMWR 2000;49:622, 631.
Verstraeten T, Davis RL, DeStefano F, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health
maintenance organization databases. Pediatrics 2003;112:1039--104.
McCormick M, Bayer R, Berg A, et al. Report of the Institute of
Medicine. Immunization Safety Review: Vaccines and Autism.
Washington, DC: National Academy Press; 2004.
Vesikari T. Randomized, double-blind, placebo-controlled trial of the safety, transmissibility and phenotypic stability of a live, attenuated,
cold-adapted influenza virus vaccine (CAIV-T) in children attending day care [Abstract G-450]. Presented at the 41st Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy (ICAAC); 2001.
Talbot TR, Crocker DD, Peters J. Degree and duration of mucosal shedding following use of trivalent intranasal live attenuated influenza
vaccine in adults [Abstract]. Presented at 14th Annual Meeting, Society for Health-care Epidemiology in America, Philadelphia, Pennsylvania; 2004.
Ali T, Scott N, Kallas W, et al. Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist).
Clin Infect Dis 2004;38:760--2.
Cha TA, Kao K, Zhao J, et al. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin
Buonagurio DA, O'Neill RE, Shutyak L, et al. Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent
vaccine administered to children in a day care setting. Virology 2006;347:296--306.
King JC Jr, Fast PE, Zangwill KM, et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated
influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001;20:1124--31.
Redding G, Walker RE, Hessel C, et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with
asthma. Pediatr Infect Dis J 2002;21:44--8.
Piedra PA, Yan L, Kotloff K, et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 2002;110:662--72.
Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and
adolescents. Pediatr Infect Dis J 2004;23:138--44.
Belshe RB, Nichol KL, Black SB, et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an
indicated population aged 5--49 years. Clin Infect Dis 2004;39:920--7.
Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9
years, and 10 to 18 years of age in a community-based, nonrandomized, open-label tiral. Pediatrics 2005;11:397--407.
Jackson LA, Holmes SJ, Mendelman PM, et al. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in
addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 1999;17:1905--9.
King JC Jr, Treanor J, Fast PE, et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine,
trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect
Izurieta HS, Haber P, Ball R, et al. Post-licensure surveillance of the first live, cold-adapted influenza vaccine in the U.S.
[Abstract]. Pharmacoepidemiology and Drug Safety 2004;13:S145.
Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005;294:2720--5.
McElhaney JE, Gravenstein S, Upshaw CM, et al. Immune response to influenza vaccination in institutionalized elderly: effect on different
T-cell subsets. Vaccine 1998;16:403--9.
Gross PA, Russo C, Dran S, et al. Time to earliest peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab
Brokstad KA, Cox RJ, Olofsson J, et al. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect
Lawson F, Baker V, Au D, et al. Standing orders for influenza vaccination increased vaccination rates in inpatient settings compared
with community rates. J Gerontol A Biol Sci Med Sci 2000;55:M522--6.
Centers for Medicare and Medicaid Services. Medicare and Medicaid Programs; Condition of Participation: Immunization Standard for Long
Term Care Facilities. Final rule. Federal Register 2005;70:58834--52.
Centers for Medicare and Medicaid Services. Medicare and Medicaid programs; conditions of participation: immunization standards for
hospitals, long-term care facilities, and home health agencies. Final rule with comment period. Federal Register 2002;67:61808--14.
Fedson DS, Wajda A, Nicol JP, et al. Disparity between influenza vaccination rates and risks for influenza-associated hospital discharge and
death in Manitoba in 1982--1983. Ann Intern Med 1992;116:550--5.
Bratzler DW, Houck PM, Jiang H, et al. Failure to vaccinate Medicare inpatients: a missed opportunity. Arch Intern Med 2002;162:2349--56.
Fedson DS, Houck P, Bratzler D. Hospital-based influenza and pneumococcal vaccination: Sutton's Law applied to prevention. Infect
Control Hosp Epidemiol 2000;21:692--9.
Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006;24:1159--69.
Simonsen L, Reichert TA, Viboud C, et al. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern
Jackson LA, Jackson ML, Nelson JC, et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol
Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality
in seniors. Int J Epidemiol 2006;35:345--52.
Nichol KL, Nordin J, Mullooly J. Influence of clinical outcome and outcome period definitions on estimates of absolute clinical and
economic benefits of influenza vaccination in community dwelling elderly persons. Vaccine 2006;24:1562--8.
Thomas RE, Jefferson TO, Demicheli V, Rivetti D. Influenza vaccination for health-care workers who work with elderly people in institutions:
a systematic review. Lancet Infect Dis 2006;6:273--9.
Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine
Longini IM Jr, Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005;161:303--6.
King JC, Cummings GE, Stoddard J, et al. A pilot study of the effectiveness of a school-based influenza vaccination program.
Jordan R, Connock M, Albon E, et al. Universal vaccination of children against influenza: Are there indirect benefits to the community?
A systematic review of the evidence. Vaccine 2006;24:1047--62.
Helms CM, Guerra FA, Klein JO, et al. Strengthening the nation's influenza vaccination system: A National Vaccine Advisory
Committee assessment. Am J Prev Med 2005;29:221--6.
Uyeki TM. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza.
Pediatr Infect Dis J 2003;22:164--77.
Hayden FG, Sperber SJ, Belshe RB, et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob
Agents Chemother 1991;35:1741--7.
Degelau J, Somani SK, Cooper SL, et al. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med 1992;152:390--2.
Ziegler T, Hemphill ML, Ziegler ML, et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect
Belshe RB, Smith MH, Hall CB, et al. Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection. J
Hay AJ, Zambon MC, Wolstenholme AJ, et al. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob
Chemother 1986;18(Suppl B):19--29.
Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987;80:275--82.
Saito R, Oshitani H, Masuda H, et al. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction
fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol 2002;40:84--8.
Houck P, Hemphill M, LaCroix S, et al. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug
use. Arch Intern Med 1995;155:533--7.
Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl
J Med 1989;321:1696--702.
Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks
of influenza A (H3N2). Am J Epidemiol 1991;134:988--97.
Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant
to 4-guanidino-Neu5Ac2en. J Virol 1997;71:3385--90.
Colacino JM, Laver WG, Air GM. Selection of influenza A and B viruses for resistance to 4-guanidino-Neu5Ac2en in cell culture. J Infect
Dis 1997;176(Suppl 1):S66--8.
Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor
4-guanidino-Neu5Ac2en. J Virol 1996;70:1818--27.
Blick TJ, Tiong T, Sahasrabudhe A, et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity
to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995;214:475--84.
McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, et al. Generation and characterization of variants of NWS/G70C influenza virus after in
vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob Agents Chemother 1996;40:40--6.
Staschke KA, Colacino JM, Baxter AJ, et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en.
McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site
decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998;72:2456--62.
Tai CY, Escarpe PA, Sidwell RW, et al. Characterization of human influenza virus variants selected in vitro in the presence of the
neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998;42:3234--41.
Hay AJ, Wolstenholme AJ, Skehel JJ, et al. The molecular basis of the specific anti-influenza action of amantadine. Embo J 1985;4:3021--4.
Appleyard G. Amantadine-resistance as a genetic marker for influenza viruses. J Gen Virol 1977;36:249--55.
Roche Laboratories I. Tamiflu (oseltamivir phosphate) capsules and oral suspension [Product infomation]. Nutley, NJ: Roche Laboratories,
Barnett JM, Cadman A, Gor D, et al. Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained
during phase II clinical efficacy studies. Antimicrob Agents Chemother 2000;44:78--87.
Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza
B virus. J Infect Dis 1998;178:1257--62.
Gubareva LV, Kaiser L, Matrosovich MN, et al. Selection of influenza virus mutants in experimentally infected volunteers treated with
oseltamivir. J Infect Dis 2001;183:523--31.
Jackson HC, Roberts N, Wang ZM, et al. Management of influenza: use of new antivirals and resistance in perspective. Clin Drug
Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study.
Tisdale M. Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors. Rev Med Virol 2000;10:45--55.
Glaxo Wellcome. Relenza (zanamivir for inhalation) [Product information]. Research Triangle Park, NC: Glaxo Wellcome, Inc.; 2001.
Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition
assay. Antiviral Res 2002;53:47--61.
Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 2001;49:147--56.
Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza
virus infections. GG167 Influenza Study Group. N Engl J Med 1997;337:874--80.
MIST (Management of Influenza in the Southern Hemisphere Trialists). Randomised trial of efficacy and safety of inhaled zanamivir in
treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group.
Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment
of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000;40:42--8.
Matsumoto K, Ogawa N, Nerome K, et al. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection
in adults: results from Japan. GG167 Group. Antivir Ther 1999;4:61--8.
Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B
virus infections. J Infect Dis 1999;180:254--61.
Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis
of randomized controlled trials. Arch Intern Med 2001;161:212--7.
Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza:
a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283:1016--24.
Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled
trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355(9218):1845--50.
Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of
age: a randomized controlled trial. Pediatr Infect Dis J 2000;19:410--7.
Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20:127--33.
Murphy KR, Eivindson A, Pauksens K. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or
chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Invest 2000;20:337--49.
Uyeki T, Winquist A. Influenza. Clin Evid 2002;(7):645--51.
Cooper NJ, Sutton AJ, Abrams KR, et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B:
systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235.
Jefferson T, Demicheli V, Deeks J, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database
Syst Rev 2000;(2):CD001265.
Jefferson T, Demicheli V, Mones M, et al. Antivirals for influenza in healthy adults: systematic review. Lancet 2006;367:303--13.
Nicholson KG. Use of antivirals in influenza in the elderly: prophylaxis and therapy. Gerontology 1996;42:280--9.
Martin C, Mahoney P, Ward P. Oral oseltamivir reduces febrile illness in patients considered at high risk of influenza complications
[Abstract W22-7]. In: Options for the control of influenza IV. New York, NY: Excerpta Medica; 2001:807--11.
Gravenstein S, Johnston SL, Loeschel E, et al. Zanamivir: a review of clinical safety in individuals at high risk of developing
influenza-related complications. Drug Saf 2001;24:1113--25.
Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999--2000. J Am Geriatr
Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and
hospitalizations. Arch Intern Med 2003;163:1667--72.
Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J
Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N
Engl J Med 2000;343:1282--9.
Schilling M, Povinelli L, Krause P, et al. Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks. Vaccine
Lee C, Loeb M, Phillips A, et al. Zanamivir use during transmission of amantadine-resistant influenza A in a nursing home. Infect Control
Hosp Epidemiol 2000;21:700--4.
Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak. Can Commun Dis
Woods JM, Bethell RC, Coates JA, et al. 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of
the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993;37:1473--9.
Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and
in human respiratory epithelium. Antiviral Res 1994;25:123--31.
Mendel DB, Tai CY, Escarpe PA, et al. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice
and ferrets against influenza infection. Antimicrob Agents Chemother 1998;42:640--6.
Sidwell RW, Huffman JH, Barnard DL, et al. Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza
virus neuraminidase inhibitor. Antiviral Res 1998;37:107--20.
Hayden FG, Rollins BS. In vitro activity of the neuraminidase inhibitor GS4071 against influenza viruses [Abstract 159]. Antiviral
Mendel DB, Tai CY, Escarpe PA. GS4071 is a potent and selective inhibitor of the growth and neuraminidase activity of influenza A and B
viruses in vitro [Abstract 111]. Antiviral Res 1997;34:A73.
Ryan DM, Ticehurst J, Dempsey MH, et al. Inhibition of influenza virus replication in mice by GG167
(4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother
Ryan DM, Ticehurst J, Dempsey MH. GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of
influenza virus in ferrets. Antimicrob Agents Chemother 1995;39:2583--4.
Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled
trial. JAMA 2001;285:748--54.
Hayden FG, Jennings L, Robson R, et al. Oral oseltamivir in human experimental influenza B infection. Antivir Ther 2000;5:205--13.
Food and Drug Administration. Subject: safe and appropriate use of influenza drugs [Public Health Advisory]. Rockville, MD: US Department
of Health and Human Services, Food and Drug Administration; 2000.
Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and
B within households. J Infect Dis 2002;186:1582--8.
Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older
population. J Am Geriatr Soc 2001;49:1025--31.
Webster A, Boyce M, Edmundson S, et al. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does
not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999;36(Suppl 1):51--8.
Gomolin IH, Leib HB, Arden NH, et al. Control of influenza outbreaks in the nursing home: guidelines for diagnosis and management. J
Am Geriatr Soc 1995;43:71--4.
Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee. Infect Control
Hosp Epidemiol 1996;17:53--80.
Bradley SF. Prevention of influenza in long-term-care facilities. Long-Term-Care Committee of the Society for Health-care Epidemiology
of America. Infect Control Hosp Epidemiol 1999;20:629--37.
Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin
North Am 1987;1:459--78.
Guay DR. Amantadine and rimantadine prophylaxis of influenza A in nursing homes. A tolerability perspective. Drugs Aging 1994;5:8--19.
Patriarca PA, Kater NA, Kendal AP, et al. Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A
virus infections in nursing homes. Antimicrob Agents Chemother 1984;26:101--3.
Arden NH, Patriarca PA, Fasano MB, et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A
(H3N2) in a nursing home. Arch Intern Med 1988;148:865--8.
Patriarca PA, Arden NH, Koplan JP, et al. Prevention and control of type A influenza infections in nursing homes. Benefits and costs of
four approaches using vaccination and amantadine. Ann Intern Med 1987;107:732--40.
Shijubo N, Yamada G, Takahashi M, et al. Experience with oseltamivir in the control of nursing home influenza A outbreak. Intern
Cass LM, Efthymiopoulos C, Marsh J, et al. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir. Clin
Pharmacokinet 1999;36(Suppl 1):13--9.
Calfee DP, Peng AW, Cass LM, et al. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus
infection. Antimicrob Agents Chemother 1999;43:1616--20.
Cass LM, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to
healthy volunteers. Clin Pharmacokinet 1999;36(Suppl 1):1--11.
Bardsley-Elliot A, Noble S. Oseltamivir. Drugs 1999;58:851--60; discussion:861--2.
Cass LM, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers.
Clin Pharmacokinet 1999;36(Suppl 1):21--31.
He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin
Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled
trials for prevention and treatment. JAMA 1999;282:1240--6.
Daniel MJ, Barnett JM, Pearson BA. The low potential for drug interactions with zanamivir. Clin Pharmacokinet 1999;36(Suppl 1):41--50.
* One dose equals 0.5 mL, divided equally between each nostril.
These persons should receive inactivated influenza vaccine.
Advisory Committee on Immunization Practices
Membership List, February 2006
Chairman: Jon Abramson, MD, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Executive Secretary: Larry Pickering, MD, National Center for Immunization and Respiratory Diseases (proposed), Centers for Disease Control
and Prevention, Atlanta, Georgia.
Members: Ban Mishu Allos, MD, Vanderbilt University School of Medicine, Nashville, Tennessee; Robert Beck, Consumer Representative,
Palmyra, Virginia; Judith Campbell, MD, Baylor College of Medicine, Houston, Texas; Reginald Finger, MD, Focus on the Family, Colorado Springs,
Colorado; Janet Gildsdorf, MD, University of Michigan, Ann Arbor, Michigan; Harry Hull, MD, Minnesota Department of Health, Minneapolis,
Minnesota; Tracy Lieu, MD, Harvard Pilgrim Health Care and Harvard Medical School, Boston, Massachusetts; Edgar Marcuse, MD, Children's Hospital
and Regional Medical Center, Seattle, Washington; Dale Morse, MD, New York State Department of Health, Albany, New York; Julia Morita,
MD, Chicago Department of Health, Chicago, Illinois; Gregory Poland, MD, Mayo Clinic College of Medicine, Rochester, Minnesota; Patricia
Stinchfield, NP, Children's Hospital and Clinics, St. Paul, Minnesota; John J. Treanor, MD, University of Rochester School of Medicine and Dentistry,
Rochester, New York; and Robin Womeodu, MD, University of Tennessee Health Sciences Center, Memphis, Tennessee.
Ex-Officio Members: James E. Cheek, MD, Indian Health Service, Albuquerque, New Mexico; Wayne Hachey, DO, Department of Defense,
Falls Church, Virginia; Geoffrey S. Evans, MD, Health Resources and Services Administration, Rockville, Maryland; Bruce Gellin, MD, National
Vaccine Program Office, Washington, DC; Linda Murphy, Centers for Medicare and Medicaid Services, Baltimore, Maryland; George T. Curlin, MD,
National Institutes of Health, Bethesda, Maryland; Norman Baylor, MD, Food and Drug Administration, Bethesda, Maryland; Kristin Lee Nichol,
MD, Department of Veterans Affairs, Minneapolis, Minnesota.
Liaison Representatives: American Academy of Family Physicians, Jonathan Temte, MD, Clarence, New York, and Richard Clover, MD,
Louisville, Kentucky; American Academy of Pediatrics, Keith Powell, MD, and Carol Baker, MD, Houston, Texas; American Association of Health Plans,
Andrea Gelzer, MD, Hartford, Connecticut; American College Health Association, James C. Turner, MD, Charlottesville, Virginia; American College
of Obstetricians and Gynecologists, Stanley Gall, MD, Louisville, Kentucky; American College of Physicians, Kathleen M. Neuzil, MD,
Seattle, Washington; American Medical Association, Litjen Tan, PhD, Chicago, Illinois; American Pharmacists Association, Stephan L. Foster,
PharmD, Memphis, Tennessee; Association of Teachers of Preventive Medicine, W. Paul McKinney, MD, Louisville, Kentucky; Biotechnology
Industry Organization, Clement Lewin, PhD, Cambridge, Massachusetts; Canadian National Advisory Committee on Immunization, Monica Naus,
MD, Vancouver, British Columbia; Healthcare Infection Control Practices Advisory Committee, Steve Gordon, MD, Cleveland, Ohio; Infectious
Diseases Society of America, Samuel L. Katz, MD, Durham, North Carolina, and William Schaffner, MD, Nashville, Tennessee; London Department of
Health, David M. Salisbury, MD, London, United Kingdom; National Association of County and City Health Officials, Nancy Bennett, MD, Rochester,
New York; National Coalition for Adult Immunization, David A. Neumann, PhD, Bethesda, Maryland; National Foundation for Infectious
Diseases, William Schaffner, MD, Nashville, Tennessee; National Immunization Council and Child Health Program, Mexico, Romeo S. Rodriguez, Mexico
City, Mexico; National Medical Association, Patricia Whitley-Williams, MD, New Brunswick, New Jersey; National Vaccine Advisory Committee,
Charles Helms, MD, PhD, Iowa City, Iowa; Pharmaceutical Research and Manufacturers of America, Damian A. Braga, Swiftwater, Pennsylvania, and
Peter Paradiso, PhD, Collegeville, Pennsylvania; and Society for Adolescent Medicine, Amy Middleman, MD, Houston, Texas.
ACIP Influenza Working Group
Chair: Ban Mishu Allos, MD, Nashville, Tennessee.
Members: Jon Abramson, MD, Winston-Salem, North Carolina; Nancy Bennett, MD, Rochester, New York; Henry Bernstein, DO, Lebanon,
New Hampshire; Joseph Bresee, MD, Atlanta, Georgia; Angela Calugar, MD, Atlanta, GA; Richard Clover, MD, Louisville, Kentucky; Nancy Cox,
PhD, Atlanta, Georgia; Therese Cvetkovich, MD, Rockville, Maryland; Kathryn Edwards, MD, Nashville, Tennessee; Stanley Gall, MD,
Louisville, Kentucky; Antonia Geber, MD, Rockville, Maryland; Penina Haber, MPH, Atlanta, Georgia; Guillermo Herrera, MD, Atlanta, Georgia; Harry
Hull, MD, St. Paul, Minnesota; Marika Iwane, PhD, Atlanta, Georgia; Jim LeDuc, PhD, Atlanta, Georgia; Susan Lett, MD, Boston, Massachusetts;
Roland Levandowski, MD, Bethesda, Maryland; Alison Mawle, PhD, Atlanta, Georgia; Kathleen Neuzil, MD, Seattle, Washington; Kristin Lee Nichol,
MD, Minneapolis, Minnesota; William Schaffner, MD, Nashville, Tennessee; Benjamin Schwartz, MD, Atlanta, Georgia; David Shay, MD,
Atlanta, Georgia; Nicole Smith, PhD, Atlanta, Georgia; Ray Strikas, MD, Atlanta, Georgia; Litjen Tan, PhD, Chicago, Illinois; John Treanor, MD,
Rochester, New York; and Greg Wallace, MD, Atlanta, Georgia.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to